{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "1f40cd1d",
   "metadata": {},
   "outputs": [],
   "source": [
    "from bs4 import BeautifulSoup\n",
    "import requests\n",
    "from pypdf import PdfReader\n",
    "import io\n",
    "from tabula import read_pdf\n",
    "import pandas as pd\n",
    "import spacy \n",
    "from spacy.training import Example\n",
    "from spacy import displacy\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "38521963",
   "metadata": {},
   "source": [
    "## Extract 10 most recent submissions from medRxiv medical papers - put into dataframe"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "d69a10d7",
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_article_text():\n",
    "\n",
    "    res = requests.get('https://www.medrxiv.org/archive')\n",
    "    content = res.content\n",
    "    soup = BeautifulSoup(content)\n",
    "    \n",
    "    a = soup.find_all('a', {\"class\": \"highwire-cite-linked-title\"})\n",
    "    b = soup.find_all('span',{\"class\":'highwire-citation-authors'})\n",
    "    c = soup.find_all('span', {\"class\": \"highwire-cite-metadata-doi highwire-cite-metadata\"})\n",
    "    \n",
    "    assert len(a) > 0, 'No Articles Found'\n",
    "    assert len(a) == len(b) == len(c), 'Mismatched article metadata'\n",
    "\n",
    "    list_dict = []\n",
    "    for ix,(i,j,k) in enumerate(zip(a,b,c)):\n",
    "        list_dict.append({'title':i.text,'authors':j.text,'href':k.text.partition('doi: ')[2].strip().replace('doi.org','www.medrxiv.org/content') +'v1','full_pdf':k.text.partition('doi: ')[2].strip().replace('doi.org','www.medrxiv.org/content') + 'v1.full.pdf'})\n",
    "\n",
    "    return pd.DataFrame(list_dict)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "55445aa9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>title</th>\n",
       "      <th>authors</th>\n",
       "      <th>href</th>\n",
       "      <th>full_pdf</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PREVALENCE OF DEPRESSION AND ANXIETY IN COLOMB...</td>\n",
       "      <td>Sandra Martínez-Cabezas, Mónica Pinilla-Roncan...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Peruvian National Survey of Mental Health and ...</td>\n",
       "      <td>Victor Orlando Cruz, Andres Pariamachi, Nataly...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The impact of prolonged walking on fasting pla...</td>\n",
       "      <td>Anxious J. Niwaha, Lauren R. Rodgers, Andrew T...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>A unique cytotoxic CD4+ T cells signature defi...</td>\n",
       "      <td>Sarah Baird, Caroline L Ashley, Felix Marsh-Wa...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Epidemiology and aetiology of moderate to seve...</td>\n",
       "      <td>Siobhan  Lindsay Johnstone, Linda Erasmus, Jun...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Drug-combination wide association studies of c...</td>\n",
       "      <td>Rachel D Melamed, Panagiotis Nikolaos Lalagkas</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2022.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2022.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Vitamin B12 in pregnancy and its relationship ...</td>\n",
       "      <td>Rameesha Muzaffar, Jameeha Khursheed, Anum Yousaf</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Association of Cancer History with Structural ...</td>\n",
       "      <td>Jingxuan Wang, Kendra D Sims, Sarah F Ackley, ...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Training parameters and longitudinal adaptatio...</td>\n",
       "      <td>Pierce Boyne, Allison Miller, Sarah M Schwab, ...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Knowledge, Attitude and Practices Regarding Di...</td>\n",
       "      <td>Amey Ambike, Shirish Rao, Raghav Paranjape, Sh...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               title  \\\n",
       "0  PREVALENCE OF DEPRESSION AND ANXIETY IN COLOMB...   \n",
       "1  Peruvian National Survey of Mental Health and ...   \n",
       "2  The impact of prolonged walking on fasting pla...   \n",
       "3  A unique cytotoxic CD4+ T cells signature defi...   \n",
       "4  Epidemiology and aetiology of moderate to seve...   \n",
       "5  Drug-combination wide association studies of c...   \n",
       "6  Vitamin B12 in pregnancy and its relationship ...   \n",
       "7  Association of Cancer History with Structural ...   \n",
       "8  Training parameters and longitudinal adaptatio...   \n",
       "9  Knowledge, Attitude and Practices Regarding Di...   \n",
       "\n",
       "                                             authors  \\\n",
       "0  Sandra Martínez-Cabezas, Mónica Pinilla-Roncan...   \n",
       "1  Victor Orlando Cruz, Andres Pariamachi, Nataly...   \n",
       "2  Anxious J. Niwaha, Lauren R. Rodgers, Andrew T...   \n",
       "3  Sarah Baird, Caroline L Ashley, Felix Marsh-Wa...   \n",
       "4  Siobhan  Lindsay Johnstone, Linda Erasmus, Jun...   \n",
       "5     Rachel D Melamed, Panagiotis Nikolaos Lalagkas   \n",
       "6  Rameesha Muzaffar, Jameeha Khursheed, Anum Yousaf   \n",
       "7  Jingxuan Wang, Kendra D Sims, Sarah F Ackley, ...   \n",
       "8  Pierce Boyne, Allison Miller, Sarah M Schwab, ...   \n",
       "9  Amey Ambike, Shirish Rao, Raghav Paranjape, Sh...   \n",
       "\n",
       "                                                href  \\\n",
       "0  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "1  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "2  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "3  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "4  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "5  https://www.medrxiv.org/content/10.1101/2022.0...   \n",
       "6  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "7  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "8  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "9  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "\n",
       "                                            full_pdf  \n",
       "0  https://www.medrxiv.org/content/10.1101/2023.0...  \n",
       "1  https://www.medrxiv.org/content/10.1101/2023.0...  \n",
       "2  https://www.medrxiv.org/content/10.1101/2023.0...  \n",
       "3  https://www.medrxiv.org/content/10.1101/2023.0...  \n",
       "4  https://www.medrxiv.org/content/10.1101/2023.0...  \n",
       "5  https://www.medrxiv.org/content/10.1101/2022.0...  \n",
       "6  https://www.medrxiv.org/content/10.1101/2023.0...  \n",
       "7  https://www.medrxiv.org/content/10.1101/2023.0...  \n",
       "8  https://www.medrxiv.org/content/10.1101/2023.0...  \n",
       "9  https://www.medrxiv.org/content/10.1101/2023.0...  "
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extract_article_text()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "9d22dff9",
   "metadata": {},
   "outputs": [],
   "source": [
    "df1 = extract_article_text()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2d5ebca6",
   "metadata": {},
   "source": [
    "## Loop through above df preview papers and extract abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "56ba484b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def access_archive_listing(input_df):\n",
    "\n",
    "    abstracts = []  \n",
    "    for ix,href in enumerate(input_df['href']):\n",
    "        res = requests.get(href)\n",
    "        content = res.content\n",
    "        soup = BeautifulSoup(content)\n",
    "        for ix,i in enumerate(soup.find_all('div',{\"class\":\"section abstract\"})):\n",
    "            abstracts.append(i.text.partition('Abstract')[2].replace('\\n',''))\n",
    "\n",
    "    abstracts = list(set(abstracts))\n",
    "\n",
    "    try:\n",
    "        assert len(abstracts) == len(input_df['href']),f\"Warning: # Abstracts != # Links {len(abstracts),len(input_df['href'])}\"\n",
    "    except Exception as e:\n",
    "        print(e)\n",
    "\n",
    "    input_df['abstract'] = abstracts\n",
    "\n",
    "    return input_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "5164232c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>title</th>\n",
       "      <th>authors</th>\n",
       "      <th>href</th>\n",
       "      <th>full_pdf</th>\n",
       "      <th>abstracts</th>\n",
       "      <th>abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PREVALENCE OF DEPRESSION AND ANXIETY IN COLOMB...</td>\n",
       "      <td>Sandra Martínez-Cabezas, Mónica Pinilla-Roncan...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>AimsIn many low-income countries, fasting gluc...</td>\n",
       "      <td>AimsIn many low-income countries, fasting gluc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Peruvian National Survey of Mental Health and ...</td>\n",
       "      <td>Victor Orlando Cruz, Andres Pariamachi, Nataly...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>Background and objectives. SARS-CoV-2 infectio...</td>\n",
       "      <td>Background and objectives. SARS-CoV-2 infectio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>The impact of prolonged walking on fasting pla...</td>\n",
       "      <td>Anxious J. Niwaha, Lauren R. Rodgers, Andrew T...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>Diarrhoea is a recognised complication of HIV-...</td>\n",
       "      <td>Diarrhoea is a recognised complication of HIV-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>A unique cytotoxic CD4+ T cells signature defi...</td>\n",
       "      <td>Sarah Baird, Caroline L Ashley, Felix Marsh-Wa...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>Background: Peru is the worst affected country...</td>\n",
       "      <td>Background: Peru is the worst affected country...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Epidemiology and aetiology of moderate to seve...</td>\n",
       "      <td>Siobhan  Lindsay Johnstone, Linda Erasmus, Jun...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>Introduction:Gestational diabetes mellitus (GD...</td>\n",
       "      <td>Introduction:Gestational diabetes mellitus (GD...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Drug-combination wide association studies of c...</td>\n",
       "      <td>Rachel D Melamed, Panagiotis Nikolaos Lalagkas</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2022.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2022.0...</td>\n",
       "      <td>Background &amp; Objective: Digital Service Provid...</td>\n",
       "      <td>Background &amp; Objective: Digital Service Provid...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Vitamin B12 in pregnancy and its relationship ...</td>\n",
       "      <td>Rameesha Muzaffar, Jameeha Khursheed, Anum Yousaf</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>Combinations of common drugs may, when taken t...</td>\n",
       "      <td>Combinations of common drugs may, when taken t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Association of Cancer History with Structural ...</td>\n",
       "      <td>Jingxuan Wang, Kendra D Sims, Sarah F Ackley, ...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>The COVID-19 pandemic has impacted the well-be...</td>\n",
       "      <td>The COVID-19 pandemic has impacted the well-be...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Training parameters and longitudinal adaptatio...</td>\n",
       "      <td>Pierce Boyne, Allison Miller, Sarah M Schwab, ...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>Background: Locomotor high-intensity interval ...</td>\n",
       "      <td>Background: Locomotor high-intensity interval ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Knowledge, Attitude and Practices Regarding Di...</td>\n",
       "      <td>Amey Ambike, Shirish Rao, Raghav Paranjape, Sh...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>https://www.medrxiv.org/content/10.1101/2023.0...</td>\n",
       "      <td>Background and Objectives: Cancer survivors ar...</td>\n",
       "      <td>Background and Objectives: Cancer survivors ar...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                               title  \\\n",
       "0  PREVALENCE OF DEPRESSION AND ANXIETY IN COLOMB...   \n",
       "1  Peruvian National Survey of Mental Health and ...   \n",
       "2  The impact of prolonged walking on fasting pla...   \n",
       "3  A unique cytotoxic CD4+ T cells signature defi...   \n",
       "4  Epidemiology and aetiology of moderate to seve...   \n",
       "5  Drug-combination wide association studies of c...   \n",
       "6  Vitamin B12 in pregnancy and its relationship ...   \n",
       "7  Association of Cancer History with Structural ...   \n",
       "8  Training parameters and longitudinal adaptatio...   \n",
       "9  Knowledge, Attitude and Practices Regarding Di...   \n",
       "\n",
       "                                             authors  \\\n",
       "0  Sandra Martínez-Cabezas, Mónica Pinilla-Roncan...   \n",
       "1  Victor Orlando Cruz, Andres Pariamachi, Nataly...   \n",
       "2  Anxious J. Niwaha, Lauren R. Rodgers, Andrew T...   \n",
       "3  Sarah Baird, Caroline L Ashley, Felix Marsh-Wa...   \n",
       "4  Siobhan  Lindsay Johnstone, Linda Erasmus, Jun...   \n",
       "5     Rachel D Melamed, Panagiotis Nikolaos Lalagkas   \n",
       "6  Rameesha Muzaffar, Jameeha Khursheed, Anum Yousaf   \n",
       "7  Jingxuan Wang, Kendra D Sims, Sarah F Ackley, ...   \n",
       "8  Pierce Boyne, Allison Miller, Sarah M Schwab, ...   \n",
       "9  Amey Ambike, Shirish Rao, Raghav Paranjape, Sh...   \n",
       "\n",
       "                                                href  \\\n",
       "0  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "1  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "2  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "3  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "4  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "5  https://www.medrxiv.org/content/10.1101/2022.0...   \n",
       "6  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "7  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "8  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "9  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "\n",
       "                                            full_pdf  \\\n",
       "0  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "1  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "2  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "3  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "4  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "5  https://www.medrxiv.org/content/10.1101/2022.0...   \n",
       "6  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "7  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "8  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "9  https://www.medrxiv.org/content/10.1101/2023.0...   \n",
       "\n",
       "                                           abstracts  \\\n",
       "0  AimsIn many low-income countries, fasting gluc...   \n",
       "1  Background and objectives. SARS-CoV-2 infectio...   \n",
       "2  Diarrhoea is a recognised complication of HIV-...   \n",
       "3  Background: Peru is the worst affected country...   \n",
       "4  Introduction:Gestational diabetes mellitus (GD...   \n",
       "5  Background & Objective: Digital Service Provid...   \n",
       "6  Combinations of common drugs may, when taken t...   \n",
       "7  The COVID-19 pandemic has impacted the well-be...   \n",
       "8  Background: Locomotor high-intensity interval ...   \n",
       "9  Background and Objectives: Cancer survivors ar...   \n",
       "\n",
       "                                            abstract  \n",
       "0  AimsIn many low-income countries, fasting gluc...  \n",
       "1  Background and objectives. SARS-CoV-2 infectio...  \n",
       "2  Diarrhoea is a recognised complication of HIV-...  \n",
       "3  Background: Peru is the worst affected country...  \n",
       "4  Introduction:Gestational diabetes mellitus (GD...  \n",
       "5  Background & Objective: Digital Service Provid...  \n",
       "6  Combinations of common drugs may, when taken t...  \n",
       "7  The COVID-19 pandemic has impacted the well-be...  \n",
       "8  Background: Locomotor high-intensity interval ...  \n",
       "9  Background and Objectives: Cancer survivors ar...  "
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "access_archive_listing(df1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "a15e89f7",
   "metadata": {},
   "outputs": [],
   "source": [
    "df2 = access_archive_listing(df1)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "018fb69d",
   "metadata": {},
   "source": [
    "## Extract Paper Abstract Information Using NER Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "a30c4ad1",
   "metadata": {},
   "outputs": [],
   "source": [
    "# test_text2 = '''\n",
    "# Background and Objectives: Cancer survivors are less likely than comparably-aged individuals without a cancer history to develop Alzheimer's disease and related dementias (ADRD). We investigated the association between cancer history and structural magnetic resonance imaging (MRI) markers for ADRD risk, using linear mixed-effects models to assess differences at the mean values of MRI markers and quantile regression to examine whether the association varies across the distribution of MRI markers of brain aging. Methods: Among UK Biobank participants with ≥1 brain MRI, we considered total gray matter volume, total brain volume, hippocampal volume, white matter hyperintensity volume, and mean cortical thickness in the Alzheimer's disease (AD) signature region. Cancer history was ascertained from national registry and self-report. We first specified linear mixed models with random intercepts to assess mean differences in MRI markers according to cancer history. Next, to examine whether effects of cancer history on these markers varies across the ADRD risk distribution, we specified quantile regression models to assess differences in quantile cut-points of the distribution of MRI markers according to cancer history. Models adjusted for demographics, APOE-ε4 status, and health behaviors. Results: The sample included 42,242 MRIs on 37,588 participants with no cancer history (mean age 64.1 years), and 6,073 MRIs on 5,514 participants with a cancer diagnosis prior to MRI (mean age 66.7 years). Cancer history was associated with smaller mean hippocampal volume (b=-19 mm3, 95% confidence interval [CI]=-36, -1) and lower mean cortical thickness in the AD signature region (b=-0.004 mm, 95% CI=-0.007, -0.000). Quantile regressions indicated cancer history had larger effects on high quantiles of white matter hyperintensities (10th percentile b=-49 mm3, 95% CI=-112, 19; 90th percentile b=552 mm3, 95% CI= 250, 1002) and low quantiles of cortical thickness (10th percentile b=-0.006 mm, 95% CI=-0.011, -0.000; 90th percentile b=0.003 mm3, 95% CI=-0.003, 0.007), indicating individuals most vulnerable to ADRD were more affected by cancer history. Discussion: We found no evidence that cancer history was associated with less ADRD-related neurodegeneration. To the contrary, adults with cancer history had worse MRI indicators of dementia risk. Adverse associations were largest in the highest-risk quantiles of neuroimaging markers.\n",
    "# '''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "18260eb6",
   "metadata": {},
   "outputs": [],
   "source": [
    "abstract_ner_model = spacy.load('./abstract_ner_trainer/model/')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "9960620c",
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_abstract_entities(input_abstracts):\n",
    "    for i in input_abstracts:\n",
    "        doc1 = abstract_ner_model(i)\n",
    "        displacy.render(doc1,style = 'ent')\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "6774978f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">AimsIn many low-income countries, fasting glucose is the primary measure of glycaemic control used for treatment titration, as HbA1c is often unavailable or unaffordable. Many patients in these countries walk long distances to the clinic, but the impact of walking on fasting glucose in type 2 diabetes is unknown. We aimed to determine whether this prolonged walking affects the reliability of fasting \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plasma glucose as a measure of glycaemic control.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">METHOD_SUMM</span>\n",
       "</mark>\n",
       " MethodsIn a randomised crossover trial, the change in glucose from baseline in the fasting state was compared between walking on a treadmill at a predetermined speed of 4.5 km/hour for 1 hour and not walking (resting) in people with type 2 diabetes. The pre-specified primary outcome was glucose at 1 and 2 hours.Results45 participants were enrolled and all completed both visits. 21/45 (46.7%) were female, and the median age was 51. Glucose during and after walking was similar to glucose while at rest; glucose difference (walking minus rest) was -0.15 (95% CI: -0.55, 0.26) and -0.10 (95% CI: -0.50, 0.31) mmol/L at 1 and 2 hours respectively, p&gt;0.4 for both). ConclusionsFasting \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    plasma glucose is not meaningfully affected by prolonged walking in participants with type 2 diabetes; therefore, the reliability of fasting glucose for monitoring glycaemic burden\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">METHOD_SUMM</span>\n",
       "</mark>\n",
       " is unlikely to be altered in patients who walk to the clinic.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Background and objectives. \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2 infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " causes a spectrum of clinical disease presentation, ranging from asymptomatic to fatal. While neutralising antibody (NAb) responses correlate with protection against symptomatic and severe infection, the contribution of the T cell response to the resolution or progression of disease is still unclear. Optimal protective immunity may require activation of distinct immune pathways. As such, defining the contribution of individual T cell subsets to disease outcome is imperative to inform the development of next-generation \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19 vaccines.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " To address this, we performed immunophenotyping of T cell responses in unvaccinated individuals, representing the full spectrum of COVID-19 clinical presentation. Methods. \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Spectral cytometry was performed on peripheral blood mononuclear cell samples from patients with PCR-confirmed SARS-CoV-2 infection.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">METHOD_SUMM</span>\n",
       "</mark>\n",
       " Computational and manual analyses were used to identify \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cell populations associated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " with distinct disease states through unbiased clustering, principal component analysis and discriminant analysis. Results. Critical \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    SARS-CoV-2 infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " was characterised by an increase in activated and cytotoxic CD4+ (CTL) cells of a T follicular helper (TFH) or effector memory re-expressing CD45RA (TEMRA) phenotype. These CD4+ CTLs were largely absent in those with less severe disease. In contrast, those with asymptomatic or mild disease were associated with high proportions of naive T cells and reduced expression of activation markers. Conclusion. Highly activated and cytotoxic CD4+ T cell responses may contribute to cell-mediated host tissue damage and progression of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " Potential for induction of these detrimental T cell responses should be considered when developing and implementing effective COVID-19 control strategies.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Diarrhoea is a recognised complication of HIV-infection, yet there are limited local aetiological data in this high-risk group. These data are important for informing public health interventions and updating diagnostic and treatment guidelines. This study aimed to determine the pathogenic causes for diarrhoeal admissions in HIV-infected patients compared to hospital controls between July 2018 and November 2021.Admitted diarrhoeal cases (n=243) and non-diarrhoeal hospital controls (n=101) &gt;=5 years of age were enrolled at Kalafong, Mapulaneng and Matikwana hospitals. \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Stool specimens/\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       "rectal swabs were collected and pathogen screening performed on multiple platforms. Differences in pathogen detections between cases and controls, stratified by HIV status, were investigated.The majority (n=164, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    67.5%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       ") of diarrhoeal cases with known HIV status were HIV-infected. Pathogens could be detected in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    66.3% (n=228)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       " of specimens, with significantly higher detection in cases compared to controls (72.8% versus 50.5%, p&lt;0.001). Amongst HIV-infected participants, prevalence of Cystoisospora spp. was significantly higher in cases than controls (17.7% versus \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.0%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    p=0.028)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       ", while Schistosoma was detected more often in controls than cases (17.4% versus \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    2.4%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       ", p=0.009). Amongst the HIV-uninfected participants, prevalence of Shigella spp., \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Salmonella spp.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " and Helicobacter pylori was significantly higher in cases compared to controls (36.7% versus \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    12.0%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       ", p=0.002; 11.4% versus \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.0%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       ", p=0.012; 10.1% versus \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    0.0%\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       ", p=0.023).Diarrhoeal aetiology differed by HIV status, with Shigella spp. \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    (36.7%)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Salmonella spp.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    (11.4%)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       " having the highest prevalence amongst HIV-uninfected cases and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Shigella spp.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " (18.3%), \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cystoisospora\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    (17.7%)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONF_INT</span>\n",
       "</mark>\n",
       ", and Cryptosporidium spp. \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    (15.9%)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       " having the highest prevalence amongst HIV-infected cases. These differences should be considered for the development of diagnostic and treatment guidelines.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Background: Peru is the worst affected country by the COVID-19 pandemic showing the world highest mortality rate, thus triggering an increased mental health burden. Nevertheless, there are few population-based epidemiologic surveys of mental disorders in Peru; Therefore, nationally representative research is needed to understand the underlying population-based mental health burden and identify unmet care needs.  Objective: The present study aims to estimate the prevalence and patterns of psychiatric disorders, mental health service use, and unmet mental health care needsMethods: This cross-sectional study will collect information from a multistage random sample of 19,500 households. A child, an adolescent, an adult, and an older adult will be interviewed in the household. Trained staff will conduct face-to-face diagnostic interviews via the Preschool \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Age Psychiatric Assessment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       ", the Child and Adolescent Psychiatric Assessment, the WHO's \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Composite International Diagnostic Interview\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       ", and the Alzheimer Disease 8 Scale. In addition, descriptive and inferential analysis for complex sampling will be performed to estimate the prevalence and correlates.Ethics and dissemination: IRB will approve the research protocol before the commencement of the study. Only respondents who signed their informed consents or assents will participate in the study; The parent or guardian will \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    sign the consent for the participation of preschool children.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">STUDY_SUMM</span>\n",
       "</mark>\n",
       " The research findings will be disseminated in peer-reviewed publications, scientific reports, and presentations at national, and international meetings. In addition, de-identified data and study results will be posted on the Peruvian National Institute of Mental Health (PNIMH) website to be freely available to policymakers, researchers, and the general public.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Introduction:Gestational diabetes mellitus (GDM) is one of the most prevalent complications of pregnancy. In a joint statement released in 2018, the International Federation of Obstetrics and Gynecology (FIGO) and the International Diabetes Federation (IDF) stated that \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    high blood glucose levels during pregnancy have an impact on maternal, newborn, and child health and may contribute to the global burden\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONC_SUMM</span>\n",
       "</mark>\n",
       " of type 2 diabetes mellitus and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiovascular metabolic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " disorders in the short and long term. Objectives: The basic aim of the study is to analyze vitamin B12 in pregnancy and its relationship with maternal BMI and gestational DM.Material and methods:This cross-sectional study was conducted in THQ Hospital Deepalpur, Pakistan during March 2021 to August 2021. Record gathered from 118 hospitals with the total number of 364 women stated for the study coordinator. As per database record, 11% \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    (41 women)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       " were excluded due to initial trimester spontaneous abortion as well as \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    type 2 diabetes diagnosed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " in 16; 4% and follow up loss 2; 1%.Results:Maternal outcomes in pregnant women with type 1 diabetes and those without the disease were evaluated in this study. No maternal mortality occurred within 30 days of delivery in 630 pregnancies with type 1 diabetes. However, pregnant women with type 1 diabetes were usually at a much higher risk of developing adverse maternal events during their pregnancy than women without \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    type 1 diabetes,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " even after adjusting for age and infant sex or age, infant sex, place of residence, income level, occupation, calendar year, and Charlson comorbidity index. Conclusion:It is concluded type 1 diabetes remains a significant disease threatening pregnant women and their offspring. Clinicians should be aware of this clinical situation.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Background &amp; Objective: \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Digital Service Providers have\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " come up with certain Digital Well-Being Features as a step towards tackling harmful effects of screen overuse on physical and mental health. However, the awareness and use of the same remains scant. Our objective was to assess the knowledge, attitudes and practices regarding Digital Well-being features in the adult population of Maharashtra, India and the associations and correlations of the practice of using these features with screen time and degree of screen addiction. Methods: A \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cross-sectional online questionnaire-based study was conducted among 335 participants who were selected using quota sampling and were administered a Smartphone Addiction Scale and a self-designed questionnaire.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">METHOD_SUMM</span>\n",
       "</mark>\n",
       "Results: Knowledge attitudes were good and total of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    65.4% participants were digital wellbeing feature\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       " users. Correlation of digital hygiene score and digital wellbeing score was found neither with addiction nor with the average screen time.Interpretation &amp; Conclusion: Knowledge, attitude and practices regarding Digital Well-Being features were adequate among the urban population of Maharashtra. However, their use was not found to be associated with reduced screen time or a low screen addiction score. With further development and standardization, these features can be a useful tool for prevention of screen overuse and addiction.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Combinations of common drugs may, when taken together, have unexpected effects on diseases like cancer. It is not feasible to test for all combination drug effects in clinical trials, but in the real world, drugs are frequently taken in combination. Then, there may be undiscovered effects protecting users of drug combinations from cancer–or increasing their risk. By analyzing health claims data containing numerous people exposed to drug combinations, we have an opportunity to evaluate the association of drug combinations with cancer risk. Discovering these effects can not only contribute to prevention of cancer, but also suggest new clinical uses for drug combinations to prevent or treat cancer. Here we describe new methods for discovery of drug combination effects on cancer. Our approach emulates a randomized trial where one arm would have been assigned to take a drug alone, while the other arm takes the drug together with a second drug. Because discovery of associations from observational data is prone to spurious results due to confounding, we \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    develop a number of strategies to distinguish confounding from biomedically relevant findings.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">STUDY_SUMM</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " pandemic has impacted the well-being of millions of people around the globe. During the COVID-19 pandemic, the mental health of the population was affected, which means that governments would need to implement different actions to mitigate and treat mental health disorders result of the pandemic.  This study aims to estimate the prevalence of anxiety and depression for female and male adolescents and adults in Colombia before the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    COVID-19\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " pandemic. It also aimed to estimate the potential increase of the prevalence in each group as a result of the COVID-19 pandemic in 2020. We \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    used the Individual Registry of Health Services Delivery data from 2015 - 2021 to estimate the observed prevalence of anxiety and depression.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">METHOD_SUMM</span>\n",
       "</mark>\n",
       " Using the National Mental Health Survey 2015, we simulated the expected prevalence of anxiety and depression for adolescents (12 to 17 years) and adults (18 or older) from 2016 to 2020. We used an arithmetic static Monte Carlo simulation process to estimate the expected prevalence. The results of the analysis using revealed an important increase in the observed prevalence of these disorders for adults and adolescents and men and women between 2015 and February 2020. When we simulated different scenarios using the National Mental Health Survey and estimated the prevalence of both depression and anxiety for adults and adolescents, we found that the prevalence of depression and anxiety has had an important increase in the last five years for all groups and had an important increase during the 2020. This increase has been greater for women than for men, and for adolescents than adults.  Our results show the number of people who need potential attention from the health system in Colombia and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    highlight the importance to think about how to avoid and detect potential cases of anxiety and depression especially in female adolescents.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONC_SUMM</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Background: Locomotor high-intensity interval training (HIIT) has been shown to improve walking capacity more than moderate-intensity aerobic training (MAT) after stroke, but it is unclear which training parameter(s) should be prioritized (e.g. speed, heart rate, blood lactate, step count) and to what extent walking capacity gains are the result of neuromotor versus cardiorespiratory adaptations.Objective: Assess which training parameters and longitudinal adaptations most strongly mediate 6-minute walk distance (6MWD) gains from post-stroke HIIT.Methods: The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HIT-Stroke Trial randomized\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " 55 persons with chronic stroke and persistent walking limitations to HIIT or \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MAT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " and collected detailed training data. Blinded outcomes included 6MWD, plus measures of neuromotor gait function (e.g. fastest 10-meter gait speed) and aerobic capacity (e.g. ventilatory threshold). This ancillary analysis used structural equation models to compare mediating effects of different training parameters and longitudinal adaptations on 6MWD. Results: Net gains in 6MWD from HIIT versus \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MAT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " were primarily mediated by faster training speeds and longitudinal adaptations in neuromotor gait function. Training step count was also positively associated with 6MWD gains, but was lower with HIIT versus \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MAT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       ", which decreased the net 6MWD gain. HIIT generated higher training heart rate and lactate than \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MAT\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       ", but aerobic capacity gains were similar between groups, and 6MWD changes were not associated with training heart rate, training lactate, or aerobic adaptations.Conclusions: To increase walking capacity with post-stroke HIIT, training speed and step count appear to be the most important parameters to prioritize.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Background and Objectives: \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " survivors are less likely than comparably-aged individuals without a cancer history to develop \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Alzheimer's disease and related dementias (\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">METHOD_SUMM</span>\n",
       "</mark>\n",
       "ADRD). We investigated the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    association between cancer history and structural magnetic resonance imaging (MRI)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONC_SUMM</span>\n",
       "</mark>\n",
       " markers for ADRD risk, using linear mixed-effects models to assess differences at the mean values of MRI markers and quantile regression to examine \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    whether the association varies across the distribution of MRI markers of brain aging.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">STUDY_SUMM</span>\n",
       "</mark>\n",
       " Methods: Among UK Biobank participants with ≥1 brain MRI, we considered total gray matter volume, total brain volume, hippocampal volume, white matter hyperintensity volume, and mean cortical thickness in the Alzheimer's disease (AD) signature region. Cancer history was ascertained from national registry and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    self-report.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">METHOD_SUMM</span>\n",
       "</mark>\n",
       " We first specified linear mixed models with random intercepts to assess mean differences in MRI markers according to cancer history. Next, to examine whether effects of cancer history on these markers varies across the ADRD risk distribution, we specified quantile regression models to assess differences in quantile cut-points of the distribution of MRI markers according to cancer history. Models adjusted for demographics, APOE-ε4 status, and health behaviors.Results: The sample included 42,242 \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    MRIs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " on 37,588 participants with no cancer history (mean age 64.1 years), and 6,073 MRIs on 5,514 participants with a cancer diagnosis prior to MRI (mean age 66.7 years). Cancer history was associated with smaller mean hippocampal volume \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    (b=-19 mm3, 95% confidence interval [CI]=-36, -1)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       " and lower mean cortical thickness in the AD signature region (b=-0.004 mm, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    95% CI=-0.007\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       ", -0.000). Quantile regressions indicated cancer history had larger effects on high quantiles of white matter hyperintensities (10th percentile b=-49 mm3, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    95% CI=-112\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">RESULTS</span>\n",
       "</mark>\n",
       ", 19; 90th percentile b=552 mm3, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    95% CI= 250, 1002)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONF_INT</span>\n",
       "</mark>\n",
       " and low quantiles of cortical thickness (10th percentile b=-0.006 mm, \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    95% CI=-0.011, -0.000; 90th percentile b=0.003 mm3, 95% CI=-0.003, 0.007)\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONF_INT</span>\n",
       "</mark>\n",
       ", indicating individuals most vulnerable to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADRD\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " were more affected by cancer history. Discussion: We found no evidence that cancer history was associated with less \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ADRD-related neurodegeneration.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CONCEPT</span>\n",
       "</mark>\n",
       " To the contrary, adults with cancer history had worse MRI indicators of dementia risk. Adverse associations were largest in the highest-risk quantiles of neuroimaging markers.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "extract_abstract_entities(df2['abstract'])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7537087d",
   "metadata": {},
   "source": [
    "## Extract PDF tables "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "cbae714b",
   "metadata": {},
   "outputs": [],
   "source": [
    "def extract_pdf_tables(input_pdfs):\n",
    "\n",
    "    full_tables = []\n",
    "    for i in input_pdfs:\n",
    "        dfs = read_pdf(i, pages='all')\n",
    "        for table in dfs:\n",
    "            full_tables.append(table)\n",
    "\n",
    "    return full_tables"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "1525d2b2",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Got stderr: Feb 23, 2023 9:33:39 PM org.apache.pdfbox.pdmodel.font.PDSimpleFont toUnicode\n",
      "WARNING: No Unicode mapping for i3 (3) in font T5\n",
      "\n",
      "Got stderr: Feb 23, 2023 9:34:30 PM org.apache.fontbox.ttf.CmapSubtable processSubtype14\n",
      "WARNING: Format 14 cmap table is not supported and will be ignored\n",
      "Feb 23, 2023 9:34:31 PM org.apache.fontbox.ttf.CmapSubtable processSubtype14\n",
      "WARNING: Format 14 cmap table is not supported and will be ignored\n",
      "\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[    139                                       Data sources\n",
       " 0   140                                                NaN\n",
       " 1   141                      National mental health survey\n",
       " 2   142                                                NaN\n",
       " 3   143  We used data from the National Mental Health S...\n",
       " 4   144  national and regional levels of the country. T...\n",
       " 5   145  older with a positive dementia screen using th...\n",
       " 6   146  over 12 years of age with cognitive limitation...\n",
       " 7   147  did not speak Spanish (18). The final sample i...\n",
       " 8   148  aged 12 to 17 years and 10870 adults 18 years ...\n",
       " 9   149  excluded children from 7 to11 years old becaus...\n",
       " 10  150                                         caregiver.\n",
       " 11  151                                                NaN\n",
       " 12  152    Individual Registry of Health Services Delivery\n",
       " 13  153                                                NaN\n",
       " 14  154  The Individual Registry of Health Services Del...\n",
       " 15  155  of healthcare providers in Colombia. It includ...\n",
       " 16  156  the provision of different services. Its main ...\n",
       " 17  157  healthcare providers; therefore, the informati...\n",
       " 18  158  providers or services. However, it is the only...\n",
       " 19  159  the real use of healthcare services in the cou...,\n",
       "     161  \\\n",
       " 0   162   \n",
       " 1   163   \n",
       " 2   164   \n",
       " 3   165   \n",
       " 4   166   \n",
       " 5   167   \n",
       " 6   168   \n",
       " 7   169   \n",
       " 8   170   \n",
       " 9   171   \n",
       " 10  172   \n",
       " 11  173   \n",
       " 12  174   \n",
       " 13  175   \n",
       " 14  176   \n",
       " 15  177   \n",
       " \n",
       "    The IRHSD includes the provision of services, classified according to ICD-10 diagnosis  \n",
       " 0   (International classification of diseases 10th...                                      \n",
       " 1   sex, region of residence, and type of service ...                                      \n",
       " 2   (26), therefore, it allows the analysis of the...                                      \n",
       " 3   diagnosis, according to the type of service re...                                      \n",
       " 4                                                 NaN                                      \n",
       " 5   We used IRHSD data from 2015 to 2021 to estima...                                      \n",
       " 6   depression, with the assumption that everyone ...                                      \n",
       " 7   We analyzed out-patient and in-patient (hospit...                                      \n",
       " 8   disaggregated by type of diagnosis, sex, and a...                                      \n",
       " 9   14th, 2022 and we used the number of people wh...                                      \n",
       " 10  number of cases, given that the system compute...                                      \n",
       " 11                                                NaN                                      \n",
       " 12                               Statistical analysis                                      \n",
       " 13                                                NaN                                      \n",
       " 14                                Observed Prevalence                                      \n",
       " 15                                                NaN                                      ,\n",
       "    178  \\\n",
       " 0  179   \n",
       " 1  180   \n",
       " 2  181   \n",
       " 3  182   \n",
       " 4  183   \n",
       " \n",
       "   To estimate prevalence from 2015 to 2021, we used the total number of cases reported in the  \n",
       " 0  IRHSD with ICD-10 codes F41.1-F41.2-F41.3-F41....                                           \n",
       " 1  F322- F323- F328- F329- F330- F331- F332- F333...                                           \n",
       " 2  As denominator, we used the population project...                                           \n",
       " 3  Department of Statistics (DANE. From the Spani...                                           \n",
       " 4  de Estadística” by sex and groups of age for 2...                                           ,\n",
       "     186                                         Unnamed: 0\n",
       " 0   187                   Simulation (Expected Prevalence)\n",
       " 1   188                                                NaN\n",
       " 2   189                                                NaN\n",
       " 3   190  Using the National Mental Health Survey 2015, ...\n",
       " 4   191  anxiety and depression for adolescents (12 to ...\n",
       " 5   192  2020. We used two primary sources of informati...\n",
       " 6   193  the estimated prevalence of anxiety and depres...\n",
       " 7   194  (12), and second, the observed prevalence of d...\n",
       " 8   195  the IRHSD for each year between 2016 and 2020....\n",
       " 9   196  simulation to estimate the expected prevalence...\n",
       " 10  197  simulations in the context of mental health se...\n",
       " 11  198                                                NaN\n",
       " 12  199  We first calculated the prevalence of depressi...\n",
       " 13  200  the National Mental Health Survey (2015). We u...\n",
       " 14  201  individuals who had suffered any depression or...\n",
       " 15  202  the data was collected. Using this information...\n",
       " 16  203  pandemic), we calculated the rate of relative ...\n",
       " 17  204  minus year 1 divided by year 1) of the prevale...\n",
       " 18  205  IRHSD  for adolescents, adults, men, and women...\n",
       " 19  206  depression and anxiety for the years 2016 to 2...,\n",
       "   Unnamed: 0 Unnamed: 1                                  Women  \\\n",
       " 0       Year    Anxiety  Annual % Depression  Annual % Anxiety   \n",
       " 1        NaN        NaN                          change change   \n",
       " 2       2015       0.12                              0.05 0.14   \n",
       " 3       2016       0.12                   2.24 0.08 57.34 0.14   \n",
       " 4       2017       0.20                 71.98 0.16 109.29 0.20   \n",
       " 5       2018       0.33                 61.70 0.36 118.67 0.28   \n",
       " 6       2019       0.70                112.79 0.84 135.13 0.49   \n",
       " 7       2020       0.65                 -6.86 0.67 -20.37 0.39   \n",
       " 8       2021       1.46                123.84 1.37 106.49 0.62   \n",
       " \n",
       "                              Men  \n",
       " 0  Annual % Depression  Annual %  \n",
       " 1                 change  change  \n",
       " 2                           0.07  \n",
       " 3               -0.77 0.12 67.49  \n",
       " 4               44.40 0.14 21.30  \n",
       " 5               36.43 0.23 65.76  \n",
       " 6               79.24 0.46 94.64  \n",
       " 7             -21.26 0.31 -30.93  \n",
       " 8               60.50 0.49 56.06  ,\n",
       "   Unnamed: 0 Unnamed: 1                          Women Unnamed: 2  \\\n",
       " 0       Year    Anxiety  Annual % Depression  Annual %    Anxiety   \n",
       " 1        NaN        NaN                 change  change        NaN   \n",
       " 2       2015       0.98                           0.75       0.42   \n",
       " 3       2016       0.91               -6.36 0.84 12.11       0.39   \n",
       " 4       2017       1.16               27.16 1.06 25.94       0.52   \n",
       " 5       2018       1.40               20.25 1.42 34.11       0.68   \n",
       " 6       2019       2.18               55.90 1.95 36.78       1.04   \n",
       " 7       2020       2.14              -1.65 1.35 -30.46       1.07   \n",
       " 8       2021       2.61                21.53 1.46 7.75       1.21   \n",
       " \n",
       "                              Men  \n",
       " 0  Annual % Depression  Annual %  \n",
       " 1                 change  change  \n",
       " 2                           0.29  \n",
       " 3                -7.92 0.32 8.90  \n",
       " 4               33.21 0.41 30.21  \n",
       " 5               31.99 0.62 49.17  \n",
       " 6               52.28 0.83 34.12  \n",
       " 7               2.98 0.59 -28.09  \n",
       " 8                13.50 0.63 6.19  ,\n",
       "                     Unnamed: 0 Unnamed: 1 Unnamed: 2    Percentage  \\\n",
       " 0                          NaN       Base   Increase           NaN   \n",
       " 1                          NaN        NaN        NaN        change   \n",
       " 2                        Group       Line    2020 by           NaN   \n",
       " 3                          NaN        NaN        NaN  according to   \n",
       " 4                          NaN       2015     Lancet           NaN   \n",
       " 5                          NaN        NaN        NaN    IRHSD 2020   \n",
       " 6                          NaN        NaN        NaN           NaN   \n",
       " 7    Women (18 years or older)       2.3%      33.2%         -1.7%   \n",
       " 8      Men (18 years or older)       1.6%      28.0%          3.0%   \n",
       " 9    Female adolescents (12 to       4.9%      76.0%         -6.9%   \n",
       " 10                   17 years)        NaN        NaN           NaN   \n",
       " 11  Male adolescents (12 to 17       2.1%      59.0%        -21.3%   \n",
       " 12                      years)        NaN        NaN           NaN   \n",
       " 13                         NaN        NaN        NaN           NaN   \n",
       " 14   Women (18 years or older)       2.3%      33.2%         -1.7%   \n",
       " 15     Men (18 years or older)       1.6%      28.0%          3.0%   \n",
       " 16   Female adolescents (12 to       4.9%      76.0%         -6.9%   \n",
       " 17                   17 years)        NaN        NaN           NaN   \n",
       " 18  Male adolescents (12 to 17       2.1%      59.0%        -21.3%   \n",
       " 19                      years)        NaN        NaN           NaN   \n",
       " 20                         NaN        NaN        NaN           NaN   \n",
       " 21   Women (18 years or older)       2.3%      33.2%         -1.7%   \n",
       " 22     Men (18 years or older)       1.6%      28.0%          3.0%   \n",
       " 23   Female adolescents (12 to       4.9%      76.0%         -6.9%   \n",
       " 24                   17 years)        NaN        NaN           NaN   \n",
       " 25  Male adolescents (12 to 17       2.1%      59.0%        -21.3%   \n",
       " 26                      years)        NaN        NaN           NaN   \n",
       " \n",
       "     Unnamed: 3 Unnamed: 4       Unnamed: 5  Unnamed: 6       Unnamed: 7  \n",
       " 0    Estimated        NaN              NaN         NaN              NaN  \n",
       " 1          NaN        NaN   95% Confidence   Estimated              NaN  \n",
       " 2   result for         SD              NaN         NaN  Population 2020  \n",
       " 3          NaN        NaN         Interval  Population              NaN  \n",
       " 4         2020        NaN              NaN         NaN              NaN  \n",
       " 5          NaN        NaN              NaN         NaN              NaN  \n",
       " 6   Scenario 1        NaN              NaN         NaN              NaN  \n",
       " 7         4.9%       0.2%    4.917% 4.925%     924,253       18,781,581  \n",
       " 8         3.4%       0.2%    3.417% 3.425%     591,702       17,296,667  \n",
       " 9        12.6%       1.0%  12.549% 12.588%     298,868        2,377,905  \n",
       " 10         NaN        NaN              NaN         NaN              NaN  \n",
       " 11       4.02%       0.5%    4.011% 4.031%      99,405        2,472,245  \n",
       " 12         NaN        NaN              NaN         NaN              NaN  \n",
       " 13  Scenario 2        NaN              NaN         NaN              NaN  \n",
       " 14        6.8%       0.3%    6.847% 6.858%   1,287,053       18,781,581  \n",
       " 15        5.3%       0.3%    5.260% 5.272%     910,822       17,296,667  \n",
       " 16       23.8%       1.7%  23.767% 23.830%     565,908        2,377,905  \n",
       " 17         NaN        NaN              NaN         NaN              NaN  \n",
       " 18        6.9%       0.8%    6.882% 6.912%     170,506        2,472,245  \n",
       " 19         NaN        NaN              NaN         NaN              NaN  \n",
       " 20  Scenario 3        NaN              NaN         NaN              NaN  \n",
       " 21        7.8%       0.3%    7.806% 7.818%   1,467,180       18,781,581  \n",
       " 22        6.2%       0.4%    6.176% 6.189%   1,069,342       17,296,667  \n",
       " 23       32.3%       1.8%  32.317% 32.384%     769,274        2,377,905  \n",
       " 24         NaN        NaN              NaN         NaN              NaN  \n",
       " 25        9.0%       0.9%    8.953% 8.987%     221,752        2,472,245  \n",
       " 26         NaN        NaN              NaN         NaN              NaN  ,\n",
       "                  Unnamed: 0 Unnamed: 1   Unnamed: 2    Percentage  Unnamed: 3  \\\n",
       " 0                       NaN        NaN    Increased           NaN   Estimated   \n",
       " 1                       NaN  Base Line          NaN        change         NaN   \n",
       " 2                     Group        NaN  reported by           NaN  result for   \n",
       " 3                       NaN       2015          NaN  according to         NaN   \n",
       " 4                       NaN        NaN  Lancet 2021           NaN        2020   \n",
       " 5                       NaN        NaN          NaN   IRHSD  2020         NaN   \n",
       " 6                       NaN        NaN          NaN           NaN  Scenario 1   \n",
       " 7        Women (18 years or        NaN          NaN           NaN         NaN   \n",
       " 8                       NaN      2.23%          30%          -30%        4.0%   \n",
       " 9                    older)        NaN          NaN           NaN         NaN   \n",
       " 10  Men (18 years or older)      1.03%          21%          -28%        2.9%   \n",
       " 11   Female adolescents (12        NaN          NaN           NaN         NaN   \n",
       " 12                      NaN      1.70%          68%          -20%       15.4%   \n",
       " 13             to 17 years)        NaN          NaN           NaN         NaN   \n",
       " 14  Male adolescents (12 to        NaN          NaN           NaN         NaN   \n",
       " 15                      NaN      0.70%          56%          -31%        2.7%   \n",
       " 16                17 years)        NaN          NaN           NaN         NaN   \n",
       " 17                      NaN        NaN          NaN           NaN  Scenario 2   \n",
       " 18       Women (18 years or        NaN          NaN           NaN         NaN   \n",
       " 19                      NaN      2.23%          30%          -30%        6.9%   \n",
       " 20                   older)        NaN          NaN           NaN         NaN   \n",
       " 21  Men (18 years or older)      1.03%          21%          -28%        3.8%   \n",
       " 22   Female adolescents (12        NaN          NaN           NaN         NaN   \n",
       " 23                      NaN      1.70%          68%          -20%       31.0%   \n",
       " 24             to 17 years)        NaN          NaN           NaN         NaN   \n",
       " 25  Male adolescents (12 to        NaN          NaN           NaN         NaN   \n",
       " 26                      NaN      0.70%          56%          -31%        4.7%   \n",
       " 27                17 years)        NaN          NaN           NaN         NaN   \n",
       " 28                      NaN        NaN          NaN           NaN  Scenario 3   \n",
       " 29       Women (18 years or        NaN          NaN           NaN         NaN   \n",
       " 30                      NaN      2.23%          30%          -30%        8.8%   \n",
       " 31                   older)        NaN          NaN           NaN         NaN   \n",
       " 32  Men (18 years or older)      1.03%          21%          -28%        5.7%   \n",
       " 33   Female adolescents (12        NaN          NaN           NaN         NaN   \n",
       " 34                      NaN      1.70%          68%          -20%       46.2%   \n",
       " 35             to 17 years)        NaN          NaN           NaN         NaN   \n",
       " 36  Male adolescents (12 to        NaN          NaN           NaN         NaN   \n",
       " 37                      NaN      0.70%          56%          -31%        5.8%   \n",
       " 38                17 years)        NaN          NaN           NaN         NaN   \n",
       " \n",
       "    Unnamed: 4      Unnamed: 5  Unnamed: 6   Unnamed: 7  \n",
       " 0         NaN             NaN         NaN   Population  \n",
       " 1         NaN  95% Confidence   Estimated          NaN  \n",
       " 2          SE             NaN         NaN  Projections  \n",
       " 3         NaN        Interval  Population          NaN  \n",
       " 4         NaN             NaN         NaN         2020  \n",
       " 5         NaN             NaN         NaN          NaN  \n",
       " 6         NaN             NaN         NaN          NaN  \n",
       " 7         NaN             NaN         NaN          NaN  \n",
       " 8        0.2%     4.04% 4.05%     759,998   18,781,581  \n",
       " 9         NaN             NaN         NaN          NaN  \n",
       " 10       0.2%     2.88% 2.89%     499,688   17,296,667  \n",
       " 11        NaN             NaN         NaN          NaN  \n",
       " 12       1.4%   15.36% 15.42%     365,967    2,377,905  \n",
       " 13        NaN             NaN         NaN          NaN  \n",
       " 14        NaN             NaN         NaN          NaN  \n",
       " 15       0.5%     2.70% 2.72%      66,883    2,472,245  \n",
       " 16        NaN             NaN         NaN          NaN  \n",
       " 17        NaN             NaN         NaN          NaN  \n",
       " 18        NaN             NaN         NaN          NaN  \n",
       " 19       0.3%     6.87% 6.88%   1,291,164   18,781,581  \n",
       " 20        NaN             NaN         NaN          NaN  \n",
       " 21       0.3%     3.83% 3.84%     663,483   17,296,667  \n",
       " 22        NaN             NaN         NaN          NaN  \n",
       " 23       1.9%   30.93% 31.00%     736,217    2,377,905  \n",
       " 24        NaN             NaN         NaN          NaN  \n",
       " 25        NaN             NaN         NaN          NaN  \n",
       " 26       0.7%     4.69% 4.72%     116,263    2,472,245  \n",
       " 27        NaN             NaN         NaN          NaN  \n",
       " 28        NaN             NaN         NaN          NaN  \n",
       " 29        NaN             NaN         NaN          NaN  \n",
       " 30       0.4%     8.79% 8.81%   1,652,784   18,781,581  \n",
       " 31        NaN             NaN         NaN          NaN  \n",
       " 32       0.4%     5.67% 5.69%     982,615   17,296,667  \n",
       " 33        NaN             NaN         NaN          NaN  \n",
       " 34       1.8%   46.20% 46.27%   1,099,351    2,377,905  \n",
       " 35        NaN             NaN         NaN          NaN  \n",
       " 36        NaN             NaN         NaN          NaN  \n",
       " 37       0.9%     5.78% 5.81%     143,177    2,472,245  \n",
       " 38        NaN             NaN         NaN          NaN  ,\n",
       "     335                                         Unnamed: 0\n",
       " 0   336  When we analysed scenarios 2, we found that th...\n",
       " 1   337  individuals living with a mental health disord...\n",
       " 2   338  it is estimated that the prevalence of depress...\n",
       " 3   339  as much as 68% in female adolescents. The resu...\n",
       " 4   340  increase in the prevalence of depression prese...\n",
       " 5   341  prevalence, we obtained that as expected the i...\n",
       " 6   342  greater for female adolescents (31%), followed...\n",
       " 7   343                                            (4.7%).\n",
       " 8   344                                                NaN\n",
       " 9   345  Finally. when we analysed the results of the s...\n",
       " 10  346  of the prevalence of depression between 2016 a...\n",
       " 11  347  depression would have been like to the one cal...\n",
       " 12  348  effect of the COVID-19 pandemic), we found tha...\n",
       " 13  349  almost 9% of adult women might have depression...\n",
       " 14  350  percentage points compared to scenario 1 and m...,\n",
       "     377  \\\n",
       " 0   378   \n",
       " 1   379   \n",
       " 2   380   \n",
       " 3   381   \n",
       " 4   382   \n",
       " 5   383   \n",
       " 6   384   \n",
       " 7   385   \n",
       " 8   386   \n",
       " 9   387   \n",
       " 10  388   \n",
       " 11  389   \n",
       " 12  390   \n",
       " 13  391   \n",
       " 14  392   \n",
       " 15  393   \n",
       " 16  394   \n",
       " 17  395   \n",
       " 18  396   \n",
       " 19  397   \n",
       " 20  398   \n",
       " 21  399   \n",
       " 22  400   \n",
       " \n",
       "    Colombia has followed recommendations by WHO to design national mental health policies  \n",
       " 0   and plans (30) nonetheless, the increase in th...                                      \n",
       " 1   was only observed after the publication of the...                                      \n",
       " 2   However, it is not possible to conclude that t...                                      \n",
       " 3   policy, it can be due to a better registration...                                      \n",
       " 4                             mental health symptoms.                                      \n",
       " 5                                                 NaN                                      \n",
       " 6   It is important to keep in mind the context of...                                      \n",
       " 7   affected the provision of mental health servic...                                      \n",
       " 8   psychological care and integral health for vic...                                      \n",
       " 9   objective was to mitigate the psychosocial eff...                                      \n",
       " 10  different studies have revealed the many barri...                                      \n",
       " 11  healthcare services. Although, this program ex...                                      \n",
       " 12  of the conflict on the mental health of non-vi...                                      \n",
       " 13  Mental Health does not mention the effect of t...                                      \n",
       " 14                 other situations and context (33).                                      \n",
       " 15                                                NaN                                      \n",
       " 16  The COVID-19 pandemic brought different social...                                      \n",
       " 17  including the provision of healthcare services...                                      \n",
       " 18  to the WHO, 75% of the countries reduced the p...                                      \n",
       " 19  stopped completely (8) and so was in Colombia ...                                      \n",
       " 20  the number and type of barriers that individua...                                      \n",
       " 21  the mandatory quarantine that was established ...                                      \n",
       " 22  barriers might be one of the main reasons why ...                                      ,\n",
       "    624       Unnamed: 0\n",
       " 0  625  Emergency Cases\n",
       " 1  626              NaN,\n",
       "     79  \\\n",
       " 0   80   \n",
       " 1   81   \n",
       " 2   82   \n",
       " 3   83   \n",
       " 4   84   \n",
       " 5   85   \n",
       " 6   86   \n",
       " 7   87   \n",
       " 8   88   \n",
       " 9   89   \n",
       " 10  90   \n",
       " 11  91   \n",
       " \n",
       "    HbA1c and home capillary or subcutaneous glucose monitoring are the primary measures  \n",
       " 0   used to monitor glycaemic control and guide tr...                                    \n",
       " 1   countries. However, these approaches are often...                                    \n",
       " 2   the 432.7 million people with diabetes who liv...                                    \n",
       " 3   setting international organisations recommend ...                                    \n",
       " 4   control and titrate glucose-lowering therapy, ...                                    \n",
       " 5   monitoring for a substantial proportion of tho...                                    \n",
       " 6   In many low and middle-income countries, diabe...                                    \n",
       " 7   hospitals, and access to transport services ma...                                    \n",
       " 8   many patients will walk long distances to atte...                                    \n",
       " 9   walking result in increased glucose uptake and...                                    \n",
       " 10  remains unclear whether the fasting plasma glu...                                    \n",
       " 11  exercise such as walking in individuals with t...                                    ,\n",
       "     346  \\\n",
       " 0   347   \n",
       " 1   348   \n",
       " 2   349   \n",
       " 3   350   \n",
       " 4   351   \n",
       " 5   352   \n",
       " 6   353   \n",
       " 7   354   \n",
       " 8   355   \n",
       " 9   356   \n",
       " 10  357   \n",
       " 11  358   \n",
       " 12  359   \n",
       " 13  360   \n",
       " \n",
       "    The datasets generated during and/or analysed during the current study are available from the  \n",
       " 0         corresponding author on reasonable request.                                             \n",
       " 1                                                 NaN                                             \n",
       " 2                                     Acknowledgments                                             \n",
       " 3   This work was supported by MRFF COVID-19 Vacci...                                             \n",
       " 4   (J.A.T., C.C., M.S., A.L.F.). F.M. W. and T.M....                                             \n",
       " 5   the Advancement of Cytometry (ISAC) Marylou In...                                             \n",
       " 6   supported by Snow Medical Foundation as an inv...                                             \n",
       " 7   support of the University of Sydney Advanced C...                                             \n",
       " 8   participants for their contribution to this re...                                             \n",
       " 9                                                 NaN                                             \n",
       " 10                                                NaN                                             \n",
       " 11                                                NaN                                             \n",
       " 12                                                NaN                                             \n",
       " 13                                                NaN                                             ,\n",
       "     410   18.  \\\n",
       " 0   411   NaN   \n",
       " 1   412   NaN   \n",
       " 2   413  19.0   \n",
       " 3   414   NaN   \n",
       " 4   415   NaN   \n",
       " 5   416  20.0   \n",
       " 6   417   NaN   \n",
       " 7   418   NaN   \n",
       " 8   419  21.0   \n",
       " 9   420   NaN   \n",
       " 10  421   NaN   \n",
       " 11  422  22.0   \n",
       " 12  423   NaN   \n",
       " 13  424  23.0   \n",
       " 14  425   NaN   \n",
       " 15  426   NaN   \n",
       " 16  427  24.0   \n",
       " 17  428   NaN   \n",
       " 18  429   NaN   \n",
       " 19  430  25.0   \n",
       " 20  431   NaN   \n",
       " 21  432   NaN   \n",
       " 22  433  26.0   \n",
       " \n",
       "    Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al.  \n",
       " 0   Antigen-Specific Adaptive Immunity to SARS-CoV...                                     \n",
       " 1   with Age and Disease Severity. Cell. 2020; 183...                                     \n",
       " 2   Neidleman J, Luo X, George AF, McGregor M, Yan...                                     \n",
       " 3   SARS-CoV-2-specific T cells predict recovery f...                                     \n",
       " 4                                             109414.                                     \n",
       " 5   Kundu R, Narean JS, Wang L, Fenn J, Pillay T, ...                                     \n",
       " 6   T cells associate with protection against SARS...                                     \n",
       " 7                               Commun. 2022; 13: 80.                                     \n",
       " 8   Laing AG, Lorenc A, del Molino del Barrio I, D...                                     \n",
       " 9   COVID-19 immune signature includes association...                                     \n",
       " 10                                           1623–35.                                     \n",
       " 11  Kuchroo M, Huang J, Wong P, Grenier JC, Shung ...                                     \n",
       " 12  identifies multimodal signatures of COVID-19. ...                                     \n",
       " 13  Bergantini L, d’Alessandro M, Cameli P, Cavall...                                     \n",
       " 14  Cell Immunological Signatures in Hospitalized ...                                     \n",
       " 15                                              3182.                                     \n",
       " 16  Kaneko N, Boucau J, Kuo HH, Perugino C, Mahaja...                                     \n",
       " 17  in T cell subsets and expansion of cytotoxic C...                                     \n",
       " 18            Clinical Immunology. 2022; 237: 108991.                                     \n",
       " 19  Shenoy AT, Lyon De Ana C, Arafa EI, Salwig I, ...                                     \n",
       " 20  presentation by lung epithelial cells directs ...                                     \n",
       " 21              immunity. Nat Commun. 2021; 12: 5834.                                     \n",
       " 22  Juno JA, van Bockel D, Kent SJ, Kelleher AD, Z...                                     ,\n",
       "     435   27.  \\\n",
       " 0   436   NaN   \n",
       " 1   437   NaN   \n",
       " 2   438  28.0   \n",
       " 3   439   NaN   \n",
       " 4   440   NaN   \n",
       " 5   441  29.0   \n",
       " 6   442   NaN   \n",
       " 7   443   NaN   \n",
       " 8   444  30.0   \n",
       " 9   445   NaN   \n",
       " 10  446   NaN   \n",
       " 11  447  31.0   \n",
       " 12  448   NaN   \n",
       " 13  449   NaN   \n",
       " 14  450  32.0   \n",
       " 15  451   NaN   \n",
       " 16  452  33.0   \n",
       " 17  453   NaN   \n",
       " 18  454   NaN   \n",
       " 19  455  34.0   \n",
       " 20  456   NaN   \n",
       " 21  457  35.0   \n",
       " 22  458   NaN   \n",
       " \n",
       "    Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, et al. Imbalance  \n",
       " 0   of Regulatory and Cytotoxic SARS-CoV-2-Reactiv...                                         \n",
       " 1                                 183: 1340-1353.e16.                                         \n",
       " 2   Carsana L, Sonzogni A, Nasr A, Rossi RS, Pelle...                                         \n",
       " 3   mortem findings in a series of COVID-19 cases ...                                         \n",
       " 4        study. Lancet Infect Dis. 2020; 20: 1135–40.                                         \n",
       " 5   He J, Tsai LM, Leong YA, Hu X, Ma CS, Chevalie...                                         \n",
       " 6   CCR7loPD-1hi CXCR5+ CD4+ T Cells Indicate Tfh ...                                         \n",
       " 7   Responses upon Antigen Reexposure. Immunity. 2...                                         \n",
       " 8   Dan JM, Havenar-Daughton C, Kendric K, Al-koll...                                         \n",
       " 9   Recurrent group A Streptococcus tonsillitis is...                                         \n",
       " 10  antibody deficiency and aberrant TFH cells. Sc...                                         \n",
       " 11  Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-...                                         \n",
       " 12  Bcl-6-Expressing T Follicular Helper Cells and...                                         \n",
       " 13                                  183: 143-157.e13.                                         \n",
       " 14  Sun J, Tang X, Bai R, Liang C, Zeng L, Lin H, ...                                         \n",
       " 15  to SARS-CoV-2. Clinical Microbiology and Infec...                                         \n",
       " 16  Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, ...                                         \n",
       " 17  of T Cells in Patients With Coronavirus Diseas...                                         \n",
       " 18                                           11: 827.                                         \n",
       " 19  Takeuchi A, Saito T. CD4 CTL, a Cytotoxic Subs...                                         \n",
       " 20         and Function. Front Immunol. 2017; 8: 194.                                         \n",
       " 21  Koutsakos M, Rowntree LC, Hensen L, Chua BY, v...                                         \n",
       " 22  Integrated immune dynamics define correlates o...                                         ,\n",
       "    ++\\rFigure 4. Cytotoxic CD4and CD8T cells are expanded in critical infection. A) Frequency of\n",
       " 0   ++++++\\rGZMB PFN  CD4and CD8T cells across dis...                                           \n",
       " 1   -/lohi+\\rcells (CXCR5) and TFH cells (CXCR5) a...                                           \n",
       " 2   +++\\rGZMB PFN  CD4  TEMRA cells as a proportio...                                           \n",
       " 3   ++++\\rdifferentiation statusoftotalCD4non-TFHc...                                           \n",
       " 4   +-++-+\\rdefined as TN(CCR7 CD45RO ), TCM (CCR7...                                           \n",
       " 5   --\\r(CCR7 CD45RO ) in critical infection patie...                                           \n",
       " 6   +++++\\rdifferentiation status of total CD4  TF...                                           \n",
       " 7   +--+\\rcells by CCR7 PD-1  and CCR7 PD-1(cTFH) ...                                           \n",
       " 8   +++++\\rXY plot of correlation between GZMB PFN...                                           \n",
       " 9   +\\rand CD8 T  cells, respectively. Difference ...                                           \n",
       " 10  Wallis, with comparison of the rank mean of ex...                                           \n",
       " 11  Benjamini and Hochberg; error bars represent m...                                           ,\n",
       "      Unnamed: 0            Unnamed: 1    Unnamed: 2 Unnamed: 3 Unnamed: 4  \\\n",
       " 0      Critical                   NaN           NaN   Critical        NaN   \n",
       " 1           NaN                   NaN           NaN        NaN        NaN   \n",
       " 2        Severe                   NaN           NaN        NaN        NaN   \n",
       " 3           NaN  %  of CD4  T cells +           NaN     Severe    % CD4 +   \n",
       " 4      Moderate                   NaN      Moderate        NaN        NaN   \n",
       " 5           NaN                   NaN           NaN        NaN        NaN   \n",
       " 6          Mild                   NaN           NaN       Mild        NaN   \n",
       " 7  Asymptomatic                   NaN  Asymptomatic        NaN        NaN   \n",
       " \n",
       "   Unnamed: 5  Unnamed: 6                    T Unnamed: 7  Unnamed: 8  \\\n",
       " 0        NaN         NaN                    N        NaN         NaN   \n",
       " 1        NaN         NaN                TCM +        NaN         NaN   \n",
       " 2        NaN         NaN                  NaN        NaN         NaN   \n",
       " 3      TEMRA         NaN  % of CD4  non-T TEM         FH         NaN   \n",
       " 4        NaN         NaN                  NaN        NaN         NaN   \n",
       " 5        NaN         NaN                TEMRA        NaN         NaN   \n",
       " 6        NaN         NaN                  NaN        NaN         NaN   \n",
       " 7        NaN         NaN                  NaN        NaN         NaN   \n",
       " \n",
       "   Unnamed: 9     Unnamed: 10  \n",
       " 0        NaN             NaN  \n",
       " 1        NaN             NaN  \n",
       " 2        NaN             NaN  \n",
       " 3      cells             NaN  \n",
       " 4        NaN             NaN  \n",
       " 5        NaN  Disease status  \n",
       " 6        NaN             NaN  \n",
       " 7        NaN             NaN  ,\n",
       "     Unnamed: 0 Unnamed: 1    80  Unnamed: 2    Unnamed: 3  Unnamed: 4  \\\n",
       " 0          NaN        NaN   NaN         NaN             8         NaN   \n",
       " 1          NaN        NaN    60         NaN           NaN         NaN   \n",
       " 2          NaN        NaN   NaN         NaN             6         NaN   \n",
       " 3          NaN        NaN    40         NaN           NaN         NaN   \n",
       " 4          NaN        NaN   NaN         NaN             4         NaN   \n",
       " 5          NaN        NaN    20         NaN           NaN         NaN   \n",
       " 6          NaN        NaN   NaN         NaN             2         NaN   \n",
       " 7          NaN        NaN     0         NaN           NaN         NaN   \n",
       " 8          NaN        NaN   NaN         NaN             0         NaN   \n",
       " 9          NaN        (c)   NaN         NaN           NaN         NaN   \n",
       " 10         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 11         NaN     HLA-DR     +      0.0377  0.0488 PD-1+         NaN   \n",
       " 12         NaN        NaN   NaN      0.0384           NaN      0.0488   \n",
       " 13         NaN        NaN    30         NaN            20         NaN   \n",
       " 14         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 15         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 16         NaN        NaN   NaN         NaN            15         NaN   \n",
       " 17         NaN        NaN    20         NaN           NaN         NaN   \n",
       " 18         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 19         NaN        NaN   NaN         NaN            10         NaN   \n",
       " 20         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 21         NaN        NaN    10         NaN           NaN         NaN   \n",
       " 22         NaN        NaN   NaN         NaN             5         NaN   \n",
       " 23         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 24         NaN        NaN     0         NaN             0         NaN   \n",
       " 25         NaN        (d)   NaN         NaN           NaN         NaN   \n",
       " 26         NaN        NaN  T FH         NaN    CCR7+PD-1-         NaN   \n",
       " 27         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 28         NaN        NaN  4025         NaN           100         NaN   \n",
       " 29         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 30         NaN        NaN    20         NaN            80         NaN   \n",
       " 31         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 32         NaN        NaN    15         NaN            60         NaN   \n",
       " 33         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 34         NaN        NaN    10         NaN            40         NaN   \n",
       " 35         NaN        NaN   NaN         NaN           NaN         NaN   \n",
       " 36         NaN        NaN     5         NaN            20         NaN   \n",
       " 37         NaN        NaN     0         NaN             0         NaN   \n",
       " 38       579.0        NaN   NaN         NaN           NaN         NaN   \n",
       " \n",
       "         Unnamed: 5 Unnamed: 6  Unnamed: 7 80.1 Unnamed: 8  Unnamed: 9  \\\n",
       " 0              NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 1              NaN        NaN         NaN   60        NaN         NaN   \n",
       " 2              NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 3              NaN        NaN         NaN   40        NaN         NaN   \n",
       " 4              NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 5              NaN        NaN         NaN   20        NaN         NaN   \n",
       " 6              NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 7              NaN        NaN         NaN    0        NaN         NaN   \n",
       " 8              NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 9   % of CD4+ T FH      cells         NaN  NaN        NaN         NaN   \n",
       " 10             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 11          HLA-DR        NaN         NaN    +        NaN         NaN   \n",
       " 12             NaN         80         NaN  NaN        NaN         NaN   \n",
       " 13             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 14             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 15             NaN         60         NaN  NaN        NaN         NaN   \n",
       " 16             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 17             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 18             NaN         40         NaN  NaN        NaN         NaN   \n",
       " 19             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 20             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 21             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 22             NaN         20         NaN  NaN        NaN         NaN   \n",
       " 23             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 24             NaN        NaN         0.0  NaN        NaN         NaN   \n",
       " 25             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 26       CCR7 PD-1        NaN         NaN    -          +         NaN   \n",
       " 27             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 28             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 29             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 30             NaN         30         NaN  NaN        NaN         NaN   \n",
       " 31             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 32             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 33             NaN         20         NaN  NaN        NaN         NaN   \n",
       " 34             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 35             NaN         10         NaN  NaN        NaN         NaN   \n",
       " 36             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " 37             NaN        NaN         0.0  NaN        NaN         NaN   \n",
       " 38             NaN        NaN         NaN  NaN        NaN         NaN   \n",
       " \n",
       "     Unnamed: 10  Unnamed: 11 Unnamed: 12          80.2  Unnamed: 13  \\\n",
       " 0           NaN          NaN         NaN           NaN          NaN   \n",
       " 1           NaN          NaN         NaN            60          NaN   \n",
       " 2           NaN          NaN         NaN           NaN          NaN   \n",
       " 3           NaN          NaN         NaN            40          NaN   \n",
       " 4           NaN          NaN         NaN           NaN          NaN   \n",
       " 5           NaN          NaN         NaN            20          NaN   \n",
       " 6           NaN          NaN         NaN           NaN          NaN   \n",
       " 7           NaN          NaN         NaN             0          NaN   \n",
       " 8           NaN          NaN         NaN           NaN          NaN   \n",
       " 9           NaN  % of CD8+ T        EMRA           NaN          NaN   \n",
       " 10          NaN          NaN         NaN           NaN          NaN   \n",
       " 11          NaN          NaN        PD-1             +          NaN   \n",
       " 12          NaN          NaN         NaN           100       0.0256   \n",
       " 13          NaN          NaN         NaN           NaN          NaN   \n",
       " 14          NaN          NaN         NaN            80          NaN   \n",
       " 15          NaN          NaN         NaN           NaN          NaN   \n",
       " 16          NaN          NaN         NaN           NaN          NaN   \n",
       " 17          NaN          NaN         NaN            60          NaN   \n",
       " 18          NaN          NaN         NaN           NaN          NaN   \n",
       " 19          NaN          NaN         NaN           NaN          NaN   \n",
       " 20          NaN          NaN         NaN            40          NaN   \n",
       " 21          NaN          NaN         NaN           NaN          NaN   \n",
       " 22          NaN          NaN         NaN           NaN          NaN   \n",
       " 23          NaN          NaN         NaN            20          NaN   \n",
       " 24          NaN          NaN         NaN             0          NaN   \n",
       " 25          NaN  % of CD8+ T        EMRA           NaN          NaN   \n",
       " 26          NaN          NaN         NaN           NaN          NaN   \n",
       " 27       0.0408          NaN         NaN           NaN          NaN   \n",
       " 28          NaN          NaN         NaN           NaN          NaN   \n",
       " 29          NaN          NaN         NaN  Asymptomatic          NaN   \n",
       " 30          NaN          NaN         NaN          Mild          NaN   \n",
       " 31          NaN          NaN         NaN      Moderate          NaN   \n",
       " 32          NaN          NaN         NaN           NaN          NaN   \n",
       " 33          NaN          NaN         NaN        Severe          NaN   \n",
       " 34          NaN          NaN         NaN      Critical          NaN   \n",
       " 35          NaN          NaN         NaN           NaN          NaN   \n",
       " 36          NaN          NaN         NaN           NaN          NaN   \n",
       " 37          NaN          NaN         NaN           NaN          NaN   \n",
       " 38          NaN          NaN         NaN           NaN          NaN   \n",
       " \n",
       "     Unnamed: 14 Unnamed: 15  \n",
       " 0           NaN         NaN  \n",
       " 1           NaN         NaN  \n",
       " 2           NaN         NaN  \n",
       " 3           NaN         NaN  \n",
       " 4           NaN         NaN  \n",
       " 5           NaN         NaN  \n",
       " 6           NaN         NaN  \n",
       " 7           NaN         NaN  \n",
       " 8           NaN         NaN  \n",
       " 9           NaN         NaN  \n",
       " 10          NaN           +  \n",
       " 11       0.0256    % of CD8  \n",
       " 12          NaN         NaN  \n",
       " 13          NaN         NaN  \n",
       " 14          NaN         NaN  \n",
       " 15          NaN         NaN  \n",
       " 16          NaN         NaN  \n",
       " 17          NaN         NaN  \n",
       " 18          NaN         NaN  \n",
       " 19          NaN         NaN  \n",
       " 20          NaN         NaN  \n",
       " 21          NaN         NaN  \n",
       " 22          NaN         NaN  \n",
       " 23          NaN         NaN  \n",
       " 24          NaN         NaN  \n",
       " 25          NaN    % of CD8  \n",
       " 26          NaN         NaN  \n",
       " 27          NaN         NaN  \n",
       " 28          NaN         NaN  \n",
       " 29          NaN         NaN  \n",
       " 30          NaN         NaN  \n",
       " 31          NaN         NaN  \n",
       " 32          NaN         NaN  \n",
       " 33          NaN         NaN  \n",
       " 34          NaN         NaN  \n",
       " 35          NaN         NaN  \n",
       " 36          NaN         NaN  \n",
       " 37          NaN         NaN  \n",
       " 38          NaN         NaN  ,\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0, Unnamed: 1]\n",
       " Index: [],\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0, Unnamed: 1]\n",
       " Index: [],\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       "    Unnamed: 0  Unnamed: 1  Unnamed: 2  Unnamed: 3  Unnamed: 4  Unnamed: 5  \\\n",
       " 0         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 1         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 2         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 3         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 4         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " \n",
       "    Unnamed: 6  Unnamed: 7  Unnamed: 8  \n",
       " 0         NaN         NaN         NaN  \n",
       " 1         NaN         NaN         NaN  \n",
       " 2         NaN         NaN         NaN  \n",
       " 3         NaN         NaN         NaN  \n",
       " 4         NaN         NaN         NaN  ,\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0]\n",
       " Index: [],\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0, Unnamed: 1]\n",
       " Index: [],\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0, Unnamed: 1]\n",
       " Index: [],\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0, Unnamed: 1]\n",
       " Index: [],\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0]\n",
       " Index: [],\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0, Unnamed: 1]\n",
       " Index: [],\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0]\n",
       " Index: [],\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0, Unnamed: 1]\n",
       " Index: [],\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       " Empty DataFrame\n",
       " Columns: [Unnamed: 0]\n",
       " Index: [],\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       "    Unnamed: 0  Unnamed: 1\n",
       " 0         NaN         NaN,\n",
       "                 Unnamed: 0  Median age              Days post\n",
       " 0  Peak disease status (n)         NaN                    NaN\n",
       " 1                      NaN     (range)  positive swab (range)\n",
       " 2         Asymptomatic (5)  30 (25-51)              11 (5-32)\n",
       " 3                Mild (18)  31 (12-60)              15 (5-49)\n",
       " 4             Moderate (4)  58 (55-79)             21 (14-28)\n",
       " 5               Severe (5)  49 (24-69)            14 (14-112)\n",
       " 6             critical (3)  65 (59-65)                28 (28)\n",
       " 7                    Total  35 (12-79)              14 (5-12),\n",
       "          Unnamed: 0   Unnamed: 1 Unnamed: 2 Unnamed: 3    Species  \\\n",
       " 0           Product  Fluorophore      Clone   Detector        NaN   \n",
       " 1               NaN          NaN        NaN        NaN  raised in   \n",
       " 2               CD3       BUV395        SK7    UV375_C      Mouse   \n",
       " 3        Invitrogen          NaN        NaN        NaN        NaN   \n",
       " 4       LIVE/DEADTM          NaN        NaN        NaN        NaN   \n",
       " 5      Fixable Blue          NaN        NaN        NaN        NaN   \n",
       " 6               NaN          N/A        N/A      UV450      Mouse   \n",
       " 7   Dead Cell Stain          NaN        NaN        NaN        NaN   \n",
       " 8       Kit, for UV          NaN        NaN        NaN        NaN   \n",
       " 9        excitation          NaN        NaN        NaN        NaN   \n",
       " 10                †          NaN        NaN        NaN        NaN   \n",
       " 11              CD8       BUV496     RPA-T8      UV514      Mouse   \n",
       " 12               †‡          NaN        NaN        NaN        NaN   \n",
       " 13             PD-1       BUV737     EH12.2     UV737_      Mouse   \n",
       " 14              NaN          NaN        NaN        NaN        NaN   \n",
       " 15             CD19        BV510      HIB19      V510_      Mouse   \n",
       " 16              NaN          NaN        NaN        NaN        NaN   \n",
       " 17             CD56        BV605   NCAM16.2       V598      Mouse   \n",
       " 18               †‡          NaN        NaN        NaN        NaN   \n",
       " 19           HLA-DR        BV650      G46-6     V660_C      Mouse   \n",
       " 20               †‡          NaN        NaN        NaN        NaN   \n",
       " 21            Ki-67        BV711       Ki67       V720      Mouse   \n",
       " 22                †          NaN        NaN        NaN        NaN   \n",
       " 23           CD45RO        BV786      UCHL1     V780_A      Mouse   \n",
       " 24                †          NaN        NaN        NaN        NaN   \n",
       " 25              CD4   PerCPCy5.5     RPA-T4     B695_A      Mouse   \n",
       " 26               †‡          NaN        NaN        NaN        NaN   \n",
       " 27         Perforin           PE      B-D48    YG582_D      Mouse   \n",
       " 28                †          NaN        NaN        NaN        NaN   \n",
       " 29      CD197(CCR7)        PECy7     G043H7    YG780_A      Mouse   \n",
       " 30               †‡          NaN        NaN        NaN        NaN   \n",
       " 31       Granzyme B          APC    QA16A02     R660_C      Mouse   \n",
       " 32                †          NaN        NaN        NaN        NaN   \n",
       " 33            CXCR5        AF647      RF8B2       R679        Rat   \n",
       " \n",
       "         Unnamed: 4  \n",
       " 0           Source  \n",
       " 1              NaN  \n",
       " 2     BD HorizonTM  \n",
       " 3              NaN  \n",
       " 4              NaN  \n",
       " 5              NaN  \n",
       " 6       Invitrogen  \n",
       " 7              NaN  \n",
       " 8              NaN  \n",
       " 9              NaN  \n",
       " 10             NaN  \n",
       " 11    BD HorizonTM  \n",
       " 12             NaN  \n",
       " 13    BD HorizonTM  \n",
       " 14               ®  \n",
       " 15       BioLegend  \n",
       " 16               ©  \n",
       " 17  BD Biosciences  \n",
       " 18               ©  \n",
       " 19  BD Biosciences  \n",
       " 20               ®  \n",
       " 21       BioLegend  \n",
       " 22               ®  \n",
       " 23       BioLegend  \n",
       " 24               ®  \n",
       " 25       BioLegend  \n",
       " 26               ®  \n",
       " 27       BioLegend  \n",
       " 28               ®  \n",
       " 29       BioLegend  \n",
       " 30               ®  \n",
       " 31       BioLegend  \n",
       " 32               ©  \n",
       " 33  BD Biosciences  ,\n",
       "                                           Unnamed: 0  \\\n",
       " 0                        Age (years) –\\rmedian (IQR)   \n",
       " 1                                               Male   \n",
       " 2                                              Rural   \n",
       " 3                                     HIV-infected a   \n",
       " 4  Education b\\rNone\\r<= 6 years\\r7-10 years\\r>10...   \n",
       " 5  Household\\rcrowding/people\\rper room – mean\\r(...   \n",
       " 6                            Electric or gas\\rcooker   \n",
       " 7                                       Refrigerator   \n",
       " \n",
       "                                        Total (n=344)  \\\n",
       " 0                                         34 (23-47)   \n",
       " 1                                        129 (40.6%)   \n",
       " 2                                        232 (67.4%)   \n",
       " 3                                    187/316 (59.2%)   \n",
       " 4  13/337 (3.9%)\\r53/337 (15.7%)\\r107/337 (31.8%)...   \n",
       " 5                                          2.0 (1.2)   \n",
       " 6                                        296 (86.1%)   \n",
       " 7                                    289/327 (88.4%)   \n",
       " \n",
       "                                        Cases (n=243)  \\\n",
       " 0                                         36 (26-51)   \n",
       " 1                                         88 (36.2%)   \n",
       " 2                                        149 (61.3%)   \n",
       " 3                                    164/243 (67.5%)   \n",
       " 4  10/237 (4.2%)\\r47/237 (19.8%)\\r78/237 (32.9%)\\...   \n",
       " 5                                          2.0 (1.9)   \n",
       " 6                                        210 (86.4%)   \n",
       " 7                                    200/231 (86.6%)   \n",
       " \n",
       "                                     Controls (n=101)   p-value  \n",
       " 0                                         31 (17-38)  <0.001 f  \n",
       " 1                                         41 (40.6%)     0.445  \n",
       " 2                                         83 (82.2%)    <0.001  \n",
       " 3                                      23/73 (31.5%)    <0.001  \n",
       " 4  3/100 (3.0%)\\r6/100 (6.0%)\\r29/100 (29.0%)\\r62...   0.002 g  \n",
       " 5                                          2.0 (0.9)   0.733 f  \n",
       " 6                                         86 (85.1%)     0.757  \n",
       " 7                                      89/96 (92.7%)     0.115  ,\n",
       "                             Improved water\\rsource c  \\\n",
       " 0                            Treat drinking\\rwater d   \n",
       " 1  Toilet type\\rPrivate flush\\rPrivate latrine\\rC...   \n",
       " 2                                            Dairy e   \n",
       " 3                                        Deli meat e   \n",
       " 4                                             Eggs e   \n",
       " \n",
       "                                          326 (94.8%)  \\\n",
       " 0                                         45 (13.1%)   \n",
       " 1  86/337 (25.5%)\\r239/337 (70.9%)\\r8/337 (2.3%)\\...   \n",
       " 2                                        156 (45.4%)   \n",
       " 3                                        103 (29.9%)   \n",
       " 4                                        183 (53.2%)   \n",
       " \n",
       "                                          229 (94.2%)  \\\n",
       " 0                                         31 (12.8%)   \n",
       " 1  62/241 (25.7%)\\r170/241 (70.5%)\\r7/241 (2.9%)\\...   \n",
       " 2                                        107 (44.0%)   \n",
       " 3                                         79 (32.5%)   \n",
       " 4                                        127 (52.3%)   \n",
       " \n",
       "                                           97 (96.0%)  0.603 g  \n",
       " 0                                         14 (13.9%)    0.782  \n",
       " 1  24/96 (25.0%)\\r69/96 (71.9%)\\r1/96 (1.0%)\\r1/9...  0.604 g  \n",
       " 2                                         49 (48.5%)    0.447  \n",
       " 3                                         24 (23.8%)    0.107  \n",
       " 4                                         56 (55.5%)    0.590  ,\n",
       "                                           Unnamed: 0 Total (n=243)  \\\n",
       " 0  Duration of\\rsymptoms before\\radmission (days)...       4 (2-8)   \n",
       " 1                    Chronic/persistent\\rdiarrhoea a     13 (5.4%)   \n",
       " 2                                            Fatigue   182 (74.9%)   \n",
       " 3                                        Weight loss   176 (72.4%)   \n",
       " 4                                           Vomiting   172 (70.8%)   \n",
       " 5                                            Fever b   168 (69.1%)   \n",
       " \n",
       "   HIV-infected\\r(n=164) HIV-uninfected\\r(n=79)   p-value  \n",
       " 0               5 (3-8)                2 (1-4)  <0.001 d  \n",
       " 1             13 (7.9%)               0 (0.0%)   0.011 e  \n",
       " 2           124 (75.6%)             58 (73.4%)     0.712  \n",
       " 3           133 (81.1%)             43 (54.4%)    <0.001  \n",
       " 4           118 (72.0%)             54 (68.4%)     0.564  \n",
       " 5           113 (68.9%)             55 (69.6%)     0.910  ,\n",
       "              Abdominal pain  166 (68.3%)  106 (64.6%)  60 (76.0%)    0.076\n",
       " 0                    Nausea  165 (67.9%)  118 (72.0%)  47 (59.5%)    0.051\n",
       " 1     Respiratory\\rsymptoms  105 (43.2%)   77 (47.0%)  28 (35.4%)    0.090\n",
       " 2                  Headache  100 (41.2%)   68 (41.5%)  32 (40.5%)    0.887\n",
       " 3                    Chills   63 (25.9%)   48 (29.3%)  15 (19.0%)    0.087\n",
       " 4                Arthralgia   51 (21.0%)   38 (23.2%)  13 (16.5%)    0.229\n",
       " 5  Dermatological\\rsymptoms   31 (12.8%)   25 (15.2%)    6 (7.6%)    0.094\n",
       " 6                   Myalgia   24 (10.0%)    16 (9.8%)   8 (10.1%)    0.928\n",
       " 7               Dysentery c    19 (7.8%)     7 (4.3%)  12 (15.2%)    0.003\n",
       " 8    Neurological\\rsymptoms    10 (4.1%)     6 (3.7%)    4 (5.1%)  0.732 e\n",
       " 9  Painful\\rlymphadenopathy     4 (1.7%)     3 (1.9%)    1 (1.3%)  >0.99 e,\n",
       "              Unnamed: 0     Overall – na (%) Unnamed: 1 Unnamed: 2  \\\n",
       " 0                   NaN          Total Cases   Controls         p-   \n",
       " 1                   NaN      (n=344) (n=243)    (n=101)    value b   \n",
       " 2          Any pathogen       228 (66.3) 177  51 (50.5)     <0.001   \n",
       " 3                   NaN               (72.8)        NaN        NaN   \n",
       " 4                 Virus  64 (18.6) 53 (21.8)  11 (10.9)      0.018   \n",
       " 5            Adenovirus   31 (9.0) 27 (11.1)    4 (4.0)    0.038 e   \n",
       " 6      Adenovirus 40/41      3 (0.9) 3 (1.2)    0 (0.0)    0.558 e   \n",
       " 7             Norovirus    18 (5.2) 14 (5.8)    4 (4.0)    0.603 e   \n",
       " 8          Norovirus GI      4 (1.2) 2 (0.8)    2 (2.0)    0.584 e   \n",
       " 9         Norovirus GII    14 (4.1) 12 (4.9)    2 (2.0)    0.248 e   \n",
       " 10          Enterovirus    16 (4.7) 12 (4.9)    4 (4.0)    0.787 e   \n",
       " 11                  CMV      3 (0.9) 3 (1.2)    0 (0.0)    0.558 e   \n",
       " 12           Astrovirus      5 (1.5) 4 (1.7)    1 (1.0)    >0.99 e   \n",
       " 13            Rotavirus      2 (0.6) 2 (0.8)    0 (0.0)    >0.99 e   \n",
       " 14            Sapovirus      1 (0.3) 1 (0.4)    0 (0.0)    >0.99 e   \n",
       " 15    >1 virus detected      9 (2.6) 7 (2.9)    2 (2.0)    >0.99 e   \n",
       " 16             Bacteria       151 (48.9) 122  29 (28.7)     <0.001   \n",
       " 17                  NaN               (50.2)        NaN        NaN   \n",
       " 18        Shigella spp.  70 (20.4) 59 (24.3)  11 (10.9)      0.005   \n",
       " 19      Salmonella spp.    22 (6.4) 21 (8.6)    1 (1.0)    0.007 e   \n",
       " 20         C. difficile    14 (4.1) 13 (5.4)    1 (1.0)    0.074 e   \n",
       " 21        Campylobacter    13 (3.8) 12 (4.9)    1 (1.0)    0.119 e   \n",
       " 22                 STEC      2 (0.6) 0 (0.0)    2 (2.0)    0.086 e   \n",
       " 23                 ETEC     11 (3.2) 9 (3.7)    2 (2.0)    0.519 e   \n",
       " 24                 EPEC    21 (6.1) 14 (5.8)    7 (6.9)      0.631   \n",
       " 25                 EAEC  41 (11.9) 28 (11.5)  13 (12.9)      0.725   \n",
       " 26                 O157      4 (1.2) 4 (1.7)    0 (0.0)    0.325 e   \n",
       " 27          Plesiomonas      1 (0.3) 1 (0.4)    0 (0.0)    >0.99 e   \n",
       " 28  Helicobacter pylori    21 (6.1) 21 (8.6)    0 (0.0)    0.001 e   \n",
       " \n",
       "    HIV-infected – na (%) Unnamed: 3 Unnamed: 4        HIV-uninfected – na (%)  \\\n",
       " 0            Total Cases   Controls         p-           Total Cases Controls   \n",
       " 1        (n=187) (n=164)     (n=23)    value b          (n=129) (n=79) (n=50)   \n",
       " 2                138 124  14 (60.9)      0.132  84 (65.1) 53 (67.1) 31 (62.0)   \n",
       " 3          (73.8) (75.6)        NaN        NaN                            NaN   \n",
       " 4    43 (22.1) 40 (24.4)   3 (13.0)    0.296 e   20 (15.5) 13 (16.5) 7 (14.0)   \n",
       " 5    20 (10.7) 19 (11.6)    1 (4.4)    0.476 e      10 (7.8) 8 (10.1) 2 (4.0)   \n",
       " 6        2 (1.1) 2 (1.2)    0 (0.0)    >0.99 e        1 (0.8) 1 (1.3) 0 (0.0)   \n",
       " 7      13 (7.0) 13 (7.9)    0 (0.0)    0.374 e        5 (3.9) 1 (1.3) 4 (8.0)   \n",
       " 8        1 (0.5) 1 (0.6)    0 (0.0)    >0.99 e        3 (2.3) 1 (1.3) 2 (4.0)   \n",
       " 9      12 (6.4) 12 (7.3)    0 (0.0)    0.367 e        2 (1.6) 0 (0.0) 2 (4.0)   \n",
       " 10     12 (6.4) 10 (6.1)    2 (8.7)    0.645 e        4 (3.1) 2 (2.5) 2 (4.0)   \n",
       " 11       3 (1.6) 3 (1.8)    0 (0.0)    >0.99 e        0 (0.0) 0 (0.0) 0 (0.0)   \n",
       " 12       3 (1.6) 3 (1.8)    0 (0.0)    >0.99 e        2 (1.6) 1 (1.3) 1 (2.0)   \n",
       " 13       1 (0.5) 1 (0.6)    0 (0.0)    >0.99 e        1 (0.8) 1 (1.3) 0 (0.0)   \n",
       " 14       1 (0.5) 1 (0.6)    0 (0.0)    >0.99 e        0 (0.0) 0 (0.0) 0 (0.0)   \n",
       " 15       7 (3.7) 7 (4.3)    0 (0.0)    0.600 e        2 (1.6) 0 (0.0) 2 (4.0)   \n",
       " 16   87 (46.5) 76 (46.3)  11 (47.8)      0.894  61 (47.3) 46 (58.2) 15 (30.0)   \n",
       " 17                   NaN        NaN        NaN                            NaN   \n",
       " 18   32 (17.1) 30 (18.3)    2 (8.7)    0.378 e   35 (27.1) 29 (36.7) 6 (12.0)   \n",
       " 19     13 (7.0) 12 (7.3)    1 (4.4)    >0.99 e       9 (7.0) 9 (11.4) 0 (0.0)   \n",
       " 20     13 (7.0) 12 (7.3)    1 (4.4)    >0.99 e        1 (0.8) 1 (1.3) 0 (0.0)   \n",
       " 21     12 (6.4) 12 (7.3)    0 (0.0)    0.367 e        1 (0.8) 0 (0.0) 1 (2.0)   \n",
       " 22       0 (0.0) 0 (0.0)    0 (0.0)          -        2 (1.6) 0 (0.0) 2 (4.0)   \n",
       " 23       7 (3.7) 5 (3.1)    2 (8.7)    0.207 e        4 (3.1) 4 (5.1) 0 (0.0)   \n",
       " 24     15 (8.0) 11 (6.7)   4 (17.4)    0.094 e        6 (4.7) 3 (3.8) 3 (6.0)   \n",
       " 25   25 (13.4) 20 (12.2)   5 (21.7)      0.208    14 (10.9) 8 (10.1) 6 (12.0)   \n",
       " 26       3 (1.6) 3 (1.8)    0 (0.0)    >0.99 e        1 (0.8) 1 (1.3) 0 (0.0)   \n",
       " 27       1 (0.5) 1 (0.6)    0 (0.0)    >0.99 e        0 (0.0) 0 (0.0) 0 (0.0)   \n",
       " 28     13 (7.0) 13 (7.9)    0 (0.0)    0.374 e       8 (6.2) 8 (10.1) 0 (0.0)   \n",
       " \n",
       "    Unnamed: 5       p-  \n",
       " 0          p-  value C  \n",
       " 1     value b      NaN  \n",
       " 2       0.555    0.097  \n",
       " 3         NaN      NaN  \n",
       " 4       0.707    0.101  \n",
       " 5     0.314 e    0.380  \n",
       " 6     >0.99 e  0.637 e  \n",
       " 7     0.074 e    0.246  \n",
       " 8     0.559 e  0.308 e  \n",
       " 9     0.148 e  0.032 e  \n",
       " 10    0.641 e  0.296 e  \n",
       " 11          -  0.273 e  \n",
       " 12    >0.99 e  >0.99 e  \n",
       " 13    1.000 e  >0.99 e  \n",
       " 14          -  >0.99 e  \n",
       " 15    0.148 e  0.318 e  \n",
       " 16      0.002    0.894  \n",
       " 17        NaN      NaN  \n",
       " 18      0.002    0.032  \n",
       " 19    0.012 e    0.993  \n",
       " 20    >0.99 e  0.010 e  \n",
       " 21    0.388 e  0.018 e  \n",
       " 22    0.148 e  0.166 e  \n",
       " 23    0.157 e  >0.99 e  \n",
       " 24    0.676 e    0.237  \n",
       " 25      0.739    0.504  \n",
       " 26    >0.99 e  0.648 e  \n",
       " 27          -  >0.99 e  \n",
       " 28    0.023 e    >0.99  ,\n",
       "                >1 bacteria\\rdetected   45 (13.1)  37 (15.2)    8 (7.9)  \\\n",
       " 0                         Parasite d  130 (37.8)  99 (40.7)  31 (30.7)   \n",
       " 1                      Cystoisospora    29 (8.4)  29 (11.9)    0 (0.0)   \n",
       " 2              Cryptosporidium\\rspp.    30 (8.7)  27 (11.1)    3 (3.0)   \n",
       " 3                       Blastocystis   49 (14.2)  25 (10.3)  24 (23.8)   \n",
       " 4                       Giardia spp.    12 (3.5)    9 (3.7)    3 (3.0)   \n",
       " 5               Enterocytozoon\\rspp.    11 (3.2)   11 (4.5)    0 (0.0)   \n",
       " 6                        Schistosoma    12 (3.5)    5 (2.1)    7 (6.9)   \n",
       " 7                        Dientamoeba     2 (0.6)    1 (0.4)    1 (1.0)   \n",
       " 8              >1 parasite\\rdetected    19 (5.5)   13 (5.4)    6 (5.9)   \n",
       " 9   Mixed infections\\rVirus-bacteria   40 (11.6)  34 (14.0)    6 (5.9)   \n",
       " 10                    Virus-parasite   35 (10.2)  29 (11.9)    6 (5.9)   \n",
       " 11                 Bacteria-parasite   72 (20.9)  60 (24.7)  12 (11.9)   \n",
       " 12             >1 pathogen\\rdetected  115 (33.4)  92 (37.9)  23 (22.8)   \n",
       " \n",
       "         0.067  23 (12.3)  20 (12.2)  3 (13.0)  >0.99 e   11 (8.5)   8 (10.1)  \\\n",
       " 0       0.080  85 (45.5)  78 (47.6)  7 (30.4)    0.122  43 (33.3)  21 (26.6)   \n",
       " 1   <0.001\\re  29 (15.5)  20 (17.7)   0 (0.0)  0.028 e    0 (0.0)    0 (0.0)   \n",
       " 2     0.012 e  28 (15.0)  26 (15.9)   2 (8.7)  0.537 e    2 (1.6)    1 (1.3)   \n",
       " 3       0.001   15 (8.0)   12 (7.3)  3 (13.0)  0.403 e  33 (25.6)  13 (16.5)   \n",
       " 4     >0.99 e    7 (3.7)    7 (4.3)   0 (0.0)  0.600 e    4 (3.1)    2 (2.5)   \n",
       " 5     0.038 e   10 (5.4)   10 (6.1)   0 (0.0)  0.614 e    1 (0.8)    1 (1.3)   \n",
       " 6       0.025    8 (4.3)    4 (2.4)  4 (17.4)  0.009 e    4 (3.1)    1 (1.3)   \n",
       " 7     0.502 e    0 (0.0)    0 (0.0)   0 (0.0)        -    2 (1.6)    1 (1.3)   \n",
       " 8       0.827  24 (12.8)  22 (13.4)   2 (8.7)  0.744 e   10 (7.8)    6 (7.6)   \n",
       " 9       0.034  25 (13.4)  23 (14.0)   2 (8.7)  0.744 e  14 (10.9)  10 (12.7)   \n",
       " 10      0.094  25 (13.4)  23 (14.0)   2 (8.7)  0.744 e   11 (8.5)    7 (8.9)   \n",
       " 11      0.008  46 (24.6)  41 (25.0)  5 (21.7)    0.734  23 (17.8)  16 (20.3)   \n",
       " 12      0.007  73 (39.0)  66 (40.2)  7 (30.4)    0.366  40 (31.0)  26 (32.9)   \n",
       " \n",
       "       3 (6.0)  0.528 e      0.287  Unnamed: 0  \n",
       " 0   22 (44.0)    0.042      0.031         NaN  \n",
       " 1     0 (0.0)        -  <0.001\\re         NaN  \n",
       " 2     1 (2.0)  >0.99 e  <0.001\\re         NaN  \n",
       " 3   20 (40.0)    0.003     <0.001         NaN  \n",
       " 4     2 (4.0)  0.641 e    >0.99 e         NaN  \n",
       " 5     0 (0.0)  >0.99 e    0.031 e         NaN  \n",
       " 6     3 (6.0)  0.298 e    0.767 e         NaN  \n",
       " 7     1 (2.0)  >0.99 e    0.166 e         NaN  \n",
       " 8     4 (8.0)  >0.99 e      0.152         NaN  \n",
       " 9     4 (8.0)  0.564 e      0.504         NaN  \n",
       " 10    4 (8.0)  >0.99 e      0.183         NaN  \n",
       " 11   7 (14.0)    0.366      0.152         NaN  \n",
       " 12  14 (28.0)    0.557      0.143         NaN  ,\n",
       "                                 Pathogen  \\\n",
       " 0                                Viruses   \n",
       " 1                           Norovirus GI   \n",
       " 2                          Norovirus GII   \n",
       " 3                       Human astrovirus   \n",
       " 4                              Rotavirus   \n",
       " 5                       Human adenovirus   \n",
       " 6                              Sapovirus   \n",
       " 7                            Enterovirus   \n",
       " 8                                    CMV   \n",
       " 9                               Bacteria   \n",
       " 10         Campylobacer coli/jejuni/lari   \n",
       " 11              Clostridioides difficile   \n",
       " 12  Escherichia coli verotoxin positives   \n",
       " 13                       Salmonella spp.   \n",
       " 14                         Shigella spp.   \n",
       " 15       Enteroinvasive Escherichia coli   \n",
       " 16               Yersinia enterocolitica   \n",
       " 17                                  EAEC   \n",
       " 18                                  EPEC   \n",
       " 19                                  ETEC   \n",
       " 20                             STEC/VTEC   \n",
       " 21                          E. coli O157   \n",
       " 22                             Parasites   \n",
       " 23              Plesiomonas shigelloides   \n",
       " 24                 Entamoeba histolytica   \n",
       " 25                  Cryptosporidium spp.   \n",
       " 26                       Giardia lamblia   \n",
       " 27                       Vibrio cholerae   \n",
       " 28                   Helicobacter pylori   \n",
       " 29                           Schistosoma   \n",
       " 30                   Enterocytozoon spp.   \n",
       " 31             Strongyloides stercoralis   \n",
       " 32                    Cytoisospora belli   \n",
       " 33                  Blastocystis hominis   \n",
       " 34                  Dientamoeba fragilis   \n",
       " 35              Cyclospora cayentanensis   \n",
       " 36                     Hymenolepsis nana   \n",
       " \n",
       "                                      Testing platform  \n",
       " 0                                                 NaN  \n",
       " 1       FTD viral gastroenteritis, TaqMan Array Cards  \n",
       " 2       FTD viral gastroenteritis, TaqMan Array Cards  \n",
       " 3       FTD viral gastroenteritis, TaqMan Array Cards  \n",
       " 4       FTD viral gastroenteritis, TaqMan Array Cards  \n",
       " 5       FTD viral gastroenteritis, TaqMan Array Cards  \n",
       " 6       FTD viral gastroenteritis, TaqMan Array Cards  \n",
       " 7                                  TaqMan Array Cards  \n",
       " 8                                        Monoplex PCR  \n",
       " 9                                                 NaN  \n",
       " 10  FTD bacterial gastroenteritis, TaqMan Array\\rC...  \n",
       " 11  FTD bacterial gastroenteritis, TaqMan Array\\rC...  \n",
       " 12                      FTD bacterial gastroenteritis  \n",
       " 13  FTD bacterial gastroenteritis, TaqMan Array\\rC...  \n",
       " 14  FTD bacterial gastroenteritis, TaqMan Array\\rC...  \n",
       " 15        FTD bacterial gastroenteritis, TaqMan Array  \n",
       " 16  FTD bacterial gastroenteritis, TaqMan Array\\rC...  \n",
       " 17                                 TaqMan Array Cards  \n",
       " 18                                 TaqMan Array Cards  \n",
       " 19                                 TaqMan Array Cards  \n",
       " 20  FTD bacterial gastroenteritis; TaqMan Array\\rC...  \n",
       " 21                                 TaqMan Array Cards  \n",
       " 22                                                NaN  \n",
       " 23                                 TaqMan Array Cards  \n",
       " 24  FTD enteric parasites, TaqMan Array Cards,\\rSe...  \n",
       " 25  FTD enteric parasites, TaqMan Array Cards,\\rSe...  \n",
       " 26  FTD enteric parasites, TaqMan Array Cards,\\rSe...  \n",
       " 27                                 TaqMan Array Cards  \n",
       " 28                                 TaqMan Array Cards  \n",
       " 29                                 TaqMan Array Cards  \n",
       " 30                TaqMan Array Cards, SeeGene Allplex  \n",
       " 31                TaqMan Array Cards, SeeGene Allplex  \n",
       " 32                                 TaqMan Array Cards  \n",
       " 33                                    SeeGene Allplex  \n",
       " 34                                    SeeGene Allplex  \n",
       " 35                                    SeeGene Allplex  \n",
       " 36                                    SeeGene Allplex  ,\n",
       "       Ascaris lumbricoides  SeeGene Allplex\n",
       " 0              Taenia spp.  SeeGene Allplex\n",
       " 1      Trichuris trichiura  SeeGene Allplex\n",
       " 2    Ancylostoma duodenale  SeeGene Allplex\n",
       " 3  Enterobius vermicularis  SeeGene Allplex\n",
       " 4       Necator americanus  SeeGene Allplex,\n",
       "                 Unnamed: 0 CD4+ cell count a        Unnamed: 1     Unnamed: 2  \\\n",
       " 0                      NaN     <200 cells/μl  200-500 cells/μl  >500 cells/μl   \n",
       " 1                      NaN            (n=70)            (n=21)          (n=8)   \n",
       " 2              Duration of          6 (3-10)        7 (3.5-12)      5.5 (3-7)   \n",
       " 3          symptoms before               NaN               NaN            NaN   \n",
       " 4       admission – median               NaN               NaN            NaN   \n",
       " 5                    (IQR)               NaN               NaN            NaN   \n",
       " 6       Chronic/persistent          6 (8.6%)          2 (9.5%)      1 (12.5%)   \n",
       " 7                diarrhoea               NaN               NaN            NaN   \n",
       " 8              Weight loss        64 (91.4%)        17 (81.0%)      5 (62.5%)   \n",
       " 9                  Fatigue        58 (82.9%)        16 (76.2%)      5 (62.5%)   \n",
       " 10                  Nausea         6 (75.0%)        15 (71.4%)      6 (75.0%)   \n",
       " 11                Vomiting        48 (68.6%)        14 (66.7%)      6 (75.0%)   \n",
       " 12       Fever (current or        46 (65.7%)        14 (66.7%)      5 (62.5%)   \n",
       " 13                history)               NaN               NaN            NaN   \n",
       " 14          Abdominal pain        41 (58.6%)        14 (66.7%)      4 (50.0%)   \n",
       " 15             Respiratory        33 (47.1%)        12 (57.1%)      1 (12.5%)   \n",
       " 16                symptoms               NaN               NaN            NaN   \n",
       " 17                  Chills        32 (45.7%)         7 (33.3%)      3 (37.5%)   \n",
       " 18                Headache        32 (45.7%)         7 (33.3%)      4 (50.0%)   \n",
       " 19          Dermatological        13 (18.6%)         3 (14.3%)       0 (0.0%)   \n",
       " 20                symptoms               NaN               NaN            NaN   \n",
       " 21              Arthralgia        11 (15.7%)         6 (28.6%)       0 (0.0%)   \n",
       " 22                 Myalgia        11 (15.7%)          1 (4.8)%       0 (0.0%)   \n",
       " 23            Neurological          5 (7.1%)          0 (0.0%)      1 (12.5%)   \n",
       " 24                symptoms               NaN               NaN            NaN   \n",
       " 25             Dysentery b          2 (2.9%)          0 (0.0%)       0 (0.0%)   \n",
       " 26  Painful swollen glands          2 (2.9%)          0 (0.0%)       0 (0.0%)   \n",
       " \n",
       "    p-value  \n",
       " 0      NaN  \n",
       " 1      NaN  \n",
       " 2    0.822  \n",
       " 3      NaN  \n",
       " 4      NaN  \n",
       " 5      NaN  \n",
       " 6    0.855  \n",
       " 7      NaN  \n",
       " 8    0.032  \n",
       " 9    0.293  \n",
       " 10   >0.99  \n",
       " 11   >0.99  \n",
       " 12   >0.99  \n",
       " 13     NaN  \n",
       " 14   0.667  \n",
       " 15   0.097  \n",
       " 16     NaN  \n",
       " 17   0.634  \n",
       " 18   0.635  \n",
       " 19   0.494  \n",
       " 20     NaN  \n",
       " 21   0.171  \n",
       " 22   0.334  \n",
       " 23   0.347  \n",
       " 24     NaN  \n",
       " 25   >0.99  \n",
       " 26   >0.99  ,\n",
       "               Unnamed: 0 CD4+ count a - n (%)        Unnamed: 1  \\\n",
       " 0                    NaN  >500 cells/μl (n=8)  200-500 cells/μl   \n",
       " 1                    NaN                  NaN            (n=21)   \n",
       " 2           Any pathogen             5 (62.5)         12 (57.1)   \n",
       " 3                  Virus             2 (25.0)          5 (23.8)   \n",
       " 4             Adenovirus              0 (0.0)          5 (23.8)   \n",
       " 5       Adenovirus 40/41              0 (0.0)           1 (4.8)   \n",
       " 6              Norovirus              0 (0.0)           1 (4.8)   \n",
       " 7           Norovirus GI              0 (0.0)           0 (0.0)   \n",
       " 8          Norovirus GII              0 (0.0)           1 (4.8)   \n",
       " 9            Enterovirus             2 (25.0)           0 (0.0)   \n",
       " 10                   CMV              0 (0.0)           0 (0.0)   \n",
       " 11            Astrovirus              0 (0.0)           0 (0.0)   \n",
       " 12             Rotavirus              0 (0.0)           0 (0.0)   \n",
       " 13             Sapovirus              0 (0.0)           0 (0.0)   \n",
       " 14     >1 virus detected              0 (0.0)           1 (4.8)   \n",
       " 15              Bacteria             4 (50.0)          8 (38.1)   \n",
       " 16         Shigella spp.             1 (12.5)           1 (4.8)   \n",
       " 17       Salmonella spp.              0 (0.0)           0 (0.0)   \n",
       " 18          C. difficile              0 (0.0)           1 (4.8)   \n",
       " 19         Campylobacter              0 (0.0)           0 (0.0)   \n",
       " 20                  STEC              0 (0.0)           0 (0.0)   \n",
       " 21                  ETEC              0 (0.0)           0 (0.0)   \n",
       " 22                  EPEC              0 (0.0)           0 (0.0)   \n",
       " 23                  EAEC             1 (12.5)          4 (19.1)   \n",
       " 24                  O157              0 (0.0)           0 (0.0)   \n",
       " 25           Plesiomonas              0 (0.0)           1 (4.8)   \n",
       " 26   Helicobacter pylori             2 (25.0)           2 (9.5)   \n",
       " 27  >1 bacteria detected              0 (0.0)           1 (4.8)   \n",
       " 28            Parasite b             2 (25.0)          8 (38.1)   \n",
       " 29         Cystoisospora             1 (12.5)          4 (19.1)   \n",
       " 30       Cryptosporidium              0 (0.0)           1 (4.8)   \n",
       " 31                  spp.                  NaN               NaN   \n",
       " 32          Blastocystis             1 (12.5)           2 (9.5)   \n",
       " 33          Giardia spp.              0 (0.0)           1 (4.8)   \n",
       " 34   Enterocytozoon spp.              0 (0.0)           1 (4.8)   \n",
       " 35           Schistosoma              0 (0.0)           0 (0.0)   \n",
       " 36  >1 parasite detected              0 (0.0)           1 (4.8)   \n",
       " 37      Mixed infections                  NaN               NaN   \n",
       " 38        Virus-bacteria             1 (12.5)          4 (19.1)   \n",
       " 39        Virus-parasite             1 (12.5)          3 (14.3)   \n",
       " 40     Bacteria-parasite             2 (25.0)          5 (23.8)   \n",
       " \n",
       "        Unnamed: 2 p-value  \n",
       " 0   <200 cells/μl     NaN  \n",
       " 1          (n=70)     NaN  \n",
       " 2       59 (84.3)   0.022  \n",
       " 3       19 (27.1)   >0.99  \n",
       " 4        8 (11.4)   0.170  \n",
       " 5         0 (0.0)   0.293  \n",
       " 6         6 (8.6)   >0.99  \n",
       " 7         0 (0.0)       -  \n",
       " 8         6 (8.6)   >0.99  \n",
       " 9        7 (10.0)   0.068  \n",
       " 10        2 (2.9)   >0.99  \n",
       " 11        2 (2.9)   >0.99  \n",
       " 12        1 (1.4)   >0.99  \n",
       " 13        1 (1.4)   >0.99  \n",
       " 14        5 (7.1)   >0.99  \n",
       " 15      35 (50.0)   0.638  \n",
       " 16      12 (17.1)   0.389  \n",
       " 17       7 (10.0)   0.322  \n",
       " 18       9 (12.9)   0.450  \n",
       " 19        4 (5.7)   0.695  \n",
       " 20        0 (0.0)       -  \n",
       " 21        2 (2.9)   >0.99  \n",
       " 22        6 (8.6)   0.464  \n",
       " 23       8 (11.4)   0.622  \n",
       " 24        2 (2.9)   >0.99  \n",
       " 25        0 (0.0)   0.293  \n",
       " 26        4 (5.7)   0.109  \n",
       " 27      14 (20.0)   0.131  \n",
       " 28      39 (55.7)   0.145  \n",
       " 29      12 (17.1)   >0.99  \n",
       " 30      19 (27.1)   0.028  \n",
       " 31            NaN     NaN  \n",
       " 32        5 (7.1)   0.563  \n",
       " 33        4 (5.7)   >0.99  \n",
       " 34        6 (8.6)   >0.99  \n",
       " 35        1 (1.4)   >0.99  \n",
       " 36       8 (11.4)   0.611  \n",
       " 37            NaN     NaN  \n",
       " 38       9 (12.9)   0.793  \n",
       " 39      12 (17.1)   >0.99  \n",
       " 40      21 (30.0)   0.032  ,\n",
       "                  Unnamed: 0 Antiretroviral treatment a - n (%)  \\\n",
       " 0                       NaN              Yes No (n=26) p-value   \n",
       " 1                       NaN                            (n=130)   \n",
       " 2      Duration of symptoms           5 (3-8) 4.5 (2-10) 0.489   \n",
       " 3        before admission –                                NaN   \n",
       " 4              median (IQR)                                NaN   \n",
       " 5        Chronic/persistent            10 (7.7) 3 (11.5) 0.456   \n",
       " 6                 diarrhoea                                NaN   \n",
       " 7               Weight loss                108 19 (73.1) 0.231   \n",
       " 8                       NaN                             (83.1)   \n",
       " 9                   Fatigue          98 (75.4) 19 (73.1) 0.804   \n",
       " 10                   Nausea          92 (70.8) 19 (73.1) 0.813   \n",
       " 11  Fever (current or self-          89 (68.5) 20 (76.9) 0.391   \n",
       " 12  reported history in the                                NaN   \n",
       " 13            past 10 days)                                NaN   \n",
       " 14                 Vomiting          89 (68.5) 22 (84.6) 0.153   \n",
       " 15           Abdominal pain          83 (63.9) 18 (69.2) 0.600   \n",
       " 16     Respiratory symptoms          59 (45.4) 13 (50.0) 0.667   \n",
       " 17                 Headache          50 (38.5) 12 (46.2) 0.464   \n",
       " 18                   Chills           39 (30.0) 6 (23.1) 0.477   \n",
       " 19               Arthralgia            32 (24.6) 2 (7.7) 0.069   \n",
       " 20           Dermatological           21 (16.2) 2 (11.5) 0.768   \n",
       " 21                 symptoms                                NaN   \n",
       " 22                  Myalgia            14 (10.8) 1 (3.9) 0.469   \n",
       " 23              Dysentery b              6 (4.6) 1 (3.9) >0.99   \n",
       " 24             Neurological              5 (3.9) 1 (3.9) >0.99   \n",
       " 25                 symptoms                                NaN   \n",
       " 26   Painful swollen glands              3 (2.3) 0 (0.0) >0.99   \n",
       " \n",
       "    Cotrimoxazole prophylaxis a - n (%)  \n",
       " 0         Yes (n=63) No (n=88) p-value  \n",
       " 1                                  NaN  \n",
       " 2                5 (3-9) 4 (3-8) 0.410  \n",
       " 3                                  NaN  \n",
       " 4                                  NaN  \n",
       " 5                6 (9.5) 7 (8.0) 0.774  \n",
       " 6                                  NaN  \n",
       " 7            57 (90.5) 67 (76.1) 0.023  \n",
       " 8                                  NaN  \n",
       " 9            56 (88.9) 61 (69.3) 0.005  \n",
       " 10           43 (68.3) 65 (73.9) 0.451  \n",
       " 11           43 (68.3) 61 (69.3) 0.889  \n",
       " 12                                 NaN  \n",
       " 13                                 NaN  \n",
       " 14           42 (66.7) 67 (76.1) 0.200  \n",
       " 15           42 (66.7) 59 (67.1) 0.961  \n",
       " 16           29 (46.0) 41 (46.6) 0.946  \n",
       " 17           30 (47.6) 33 (37.5) 0.214  \n",
       " 18          32 (50.8) 14 (15.9) <0.001  \n",
       " 19           13 (20.6) 21 (23.9) 0.640  \n",
       " 20           10 (15.9) 14 (15.9) 0.995  \n",
       " 21                                 NaN  \n",
       " 22             10 (15.9) 6 (6.8) 0.075  \n",
       " 23               3 (4.8) 4 (4.6) >0.99  \n",
       " 24               4 (6.4) 2 (2.3) 0.236  \n",
       " 25                                 NaN  \n",
       " 26               2 (3.2) 1 (1.1) 0.571  ,\n",
       "          Unnamed: 0 Antiretroviral treatment a - n (%)  \\\n",
       " 0               NaN              No (n=26) Yes p-value   \n",
       " 1               NaN                            (n=130)   \n",
       " 2      Any pathogen          23 (88.5) 94 (72.3) 0.082   \n",
       " 3             Virus           6 (23.1) 32 (24.6) 0.868   \n",
       " 4        Adenovirus           3 (11.5) 14 (10.8) >0.99   \n",
       " 5        Adenovirus              0 (0.0) 1 (0.8) >0.99   \n",
       " 6             40/41                                NaN   \n",
       " 7         Norovirus            3 (11.5) 10 (7.7) 0.456   \n",
       " 8      Norovirus GI              0 (0.0) 1 (0.8) >0.99   \n",
       " 9     Norovirus GII             3 (11.5) 9 (6.9) 0.423   \n",
       " 10      Enterovirus              1 (3.9) 8 (6.2) >0.99   \n",
       " 11              CMV              0 (0.0) 3 (2.3) >0.99   \n",
       " 12       Astrovirus              0 (0.0) 3 (2.3) >0.99   \n",
       " 13        Rotavirus              0 (0.0) 1 (0.8) >0.99   \n",
       " 14        Sapovirus                  0 (0.0) 0 (0.0) -   \n",
       " 15         >1 virus              1 (3.9) 5 (3.9) >0.99   \n",
       " 16         detected                                NaN   \n",
       " 17         Bacteria          16 (61.5) 62 (47.7) 0.197   \n",
       " 18    Shigella spp.           5 (19.2) 24 (18.5) >0.99   \n",
       " 19  Salmonella spp.             2 (7.7) 10 (7.7) >0.99   \n",
       " 20     C. difficile             2 (7.7) 10 (7.7) >0.99   \n",
       " 21    Campylobacter             1 (3.9) 10 (7.7) 0.692   \n",
       " 22             STEC                  0 (0.0) 0 (0.0) -   \n",
       " 23             ETEC              1 (3.9) 3 (2.3) 0.522   \n",
       " 24             EPEC              2 (7.7) 8 (6.2) 0.673   \n",
       " 25             EAEC            2 (7.7) 18 (13.9) 0.531   \n",
       " 26             O157              0 (0.0) 3 (2.3) >0.99   \n",
       " 27      Plesiomonas              0 (0.0) 1 (0.8) >0.99   \n",
       " 28     Helicobacter             4 (15.4) 8 (6.2) 0.117   \n",
       " 29           pylori                                NaN   \n",
       " 30      >1 bacteria            2 (7.7) 24 (18.5) 0.252   \n",
       " 31         detected                                NaN   \n",
       " 32       Parasite b          12 (46.2) 59 (45.4) >0.99   \n",
       " 33    Cystoisospora           4 (15.4) 24 (18.5) >0.99   \n",
       " 34  Cryptosporidium                                NaN   \n",
       " 35             spp.           5 (19.2) 21 (16.2) 0.773   \n",
       " 36     Blastocystis             4 (15.4) 6 (4.6) 0.063   \n",
       " 37     Giardia spp.              1 (3.9) 5 (3.9) >0.99   \n",
       " 38   Enterocytozoon                                NaN   \n",
       " 39             spp.             0 (0.0) 10 (7.7) 0.215   \n",
       " 40      Schistosoma              0 (0.0) 4 (3.1) >0.99   \n",
       " 41      >1 parasite                                NaN   \n",
       " 42         detected             2 (7.7) 10 (7.7) >0.99   \n",
       " 43            Mixed                                NaN   \n",
       " 44       infections                                NaN   \n",
       " 45   Virus-bacteria           3 (11.5) 20 (15.4) 0.768   \n",
       " 46   Virus-parasite            2 (7.7) 19 (14.6) 0.531   \n",
       " \n",
       "    Cotrimoxazole prophylaxis a - n (%)  \n",
       " 0         No (n=88) Yes (n=63) p-value  \n",
       " 1                                  NaN  \n",
       " 2            66 (75.0) 49 (77.8) 0.693  \n",
       " 3            20 (22.7) 16 (25.4) 0.704  \n",
       " 4              9 (10.2) 8 (12.7) 0.795  \n",
       " 5                                  NaN  \n",
       " 6                 1(1.1) 0 (0.0) >0.99  \n",
       " 7               6 (6.8) 7 (11.1) 0.354  \n",
       " 8                1 (1.1) 0 (0.0) >0.99  \n",
       " 9               5 (5.7) 7 (11.1) 0.240  \n",
       " 10               4 (4.6) 4 (6.4) 0.720  \n",
       " 11               2 (2.3) 1 (1.6) >0.99  \n",
       " 12               0 (0.0) 2 (3.2) 0.172  \n",
       " 13               0 (0.0) 1 (1.6) 0.417  \n",
       " 14                   0 (0.0) 0 (0.0) -  \n",
       " 15               1 (1.1) 5 (7.9) 0.083  \n",
       " 16                                 NaN  \n",
       " 17           44 (50.0) 32 (50.8) 0.923  \n",
       " 18            18 (20.5) 9 (14.3) 0.329  \n",
       " 19               6 (6.8) 5 (7.9) >0.99  \n",
       " 20               6 (6.8) 6 (9.5) 0.544  \n",
       " 21              4 (4.6) 7 (11.1) 0.202  \n",
       " 22                   0 (0.0) 0 (0.0) -  \n",
       " 23               3 (3.4) 1 (1.6) 0.641  \n",
       " 24               6 (6.8) 5 (7.9) >0.99  \n",
       " 25            10 (11.4) 8 (12.7) 0.803  \n",
       " 26               1 (1.1) 2 (3.2) 0.571  \n",
       " 27               0 (0.0) 1 (1.6) 0.417  \n",
       " 28               6 (6.8) 6 (9.5) 0.544  \n",
       " 29                                 NaN  \n",
       " 30           11 (12.5) 13 (20.6) 0.178  \n",
       " 31                                 NaN  \n",
       " 32           33 (37.5) 37 (58.7) 0.010  \n",
       " 33           10 (11.4) 17 (26.9) 0.014  \n",
       " 34                                 NaN  \n",
       " 35           12 (13.6) 14 (22.2) 0.168  \n",
       " 36               8 (9.1) 2 (3.2) 0.195  \n",
       " 37               4 (4.6) 2 (3.2) >0.99  \n",
       " 38                                 NaN  \n",
       " 39               4 (4.6) 6 (9.5) 0.321  \n",
       " 40               3 (3.4) 1 (1.6) 0.641  \n",
       " 41                                 NaN  \n",
       " 42               7 (8.0) 5 (7.9) >0.99  \n",
       " 43                                 NaN  \n",
       " 44                                 NaN  \n",
       " 45           11 (12.5) 11 (17.5) 0.394  \n",
       " 46             8 (9.1) 11 (17.5) 0.126  ,\n",
       "   Bacteria-  8 (30.8)  34 (26.2)  0.633  19 (21.6)  22 (34.9)  0.069\n",
       " 0  parasite       NaN        NaN    NaN        NaN        NaN    NaN,\n",
       "                         Unnamed: 0 Unnamed: 1  \\\n",
       " 0                           Person      Trial   \n",
       " 1                                i          1   \n",
       " 2                                i          1   \n",
       " 3                                i          1   \n",
       " 4                                i          1   \n",
       " 5  person i is not eligible for  i          2   \n",
       " 6                              NaN        NaN   \n",
       " 7                                i          2   \n",
       " \n",
       "             Table 3: Expansion into trials  \n",
       " 0     Follow-up  Treatment Outcome comment  \n",
       " 1                                   1 A no  \n",
       " 2                                   2 A no  \n",
       " 3                                 3  A  no  \n",
       " 4                                 4  A yes  \n",
       " 5                                1  A+B no  \n",
       " 6             trials after trial 2 because  \n",
       " 7  2 A+B  no  they took the combination at  ,\n",
       "      i    2    3  A+B  yes                       Unnamed: 0\n",
       " 0    v  1.0  1.0    A   no                              NaN\n",
       " 1    v  1.0  2.0    A   no                              NaN\n",
       " 2  NaN  NaN  NaN  NaN  NaN  person v is only followed for 2\n",
       " 3    v  2.0  1.0    A   no                              NaN\n",
       " 4  NaN  NaN  NaN  NaN  NaN       windows, they have no drug\n",
       " 5    v  2.0  2.0    A   no          B or outcome in either.,\n",
       "                     Unnamed: 0            Unnamed: 1 Unnamed: 2 Unnamed: 3  \\\n",
       " 0                          NaN                   NaN        NaN        NaN   \n",
       " 1                          NaN                   NaN        NaN        NaN   \n",
       " 2                          NaN                   NaN         1%        99%   \n",
       " 3                    1 Drug(A)            Drug 2 (B)  posterior  posterior   \n",
       " 4           tiotropium_bromide     diclofenac_sodium     -0.826     -0.325   \n",
       " 5                          NaN    oseltamivir_phosph        NaN        NaN   \n",
       " 6      metformin_hydrochloride                   ate     -0.916     -0.282   \n",
       " 7               spironolactone              naproxen     -0.974     -0.186   \n",
       " 8   fluticasone_propionate_sal      mometasone_furoa        NaN        NaN   \n",
       " 9            meterol_xinafoate                    te     -0.628     -0.173   \n",
       " 10                         NaN  penicillin_v_potassi        NaN        NaN   \n",
       " 11                      niacin                    um     -0.879     -0.148   \n",
       " 12                         NaN    oseltamivir_phosph        NaN        NaN   \n",
       " 13        escitalopram_oxalate                   ate     -0.757      -0.12   \n",
       " 14                         NaN   fluticasone_propion        NaN        NaN   \n",
       " 15         pantoprazole_sodium                   ate     -0.497     -0.112   \n",
       " 16     donepezil_hydrochloride            olanzapine     -0.856      -0.11   \n",
       " 17   insulin_aspart__recombina    glucagon_hydrochlo        NaN        NaN   \n",
       " 18                          nt                  ride     -0.816     -0.104   \n",
       " 19         amlodipine_besylate    pravastatin_sodium     -0.484     -0.094   \n",
       " 20   omega-3-acid_ethyl_esters           fenofibrate     -0.844     -0.092   \n",
       " 21  fluticasone_propionate_sal                   NaN        NaN        NaN   \n",
       " 22           meterol_xinafoate              cefdinir     -0.948     -0.085   \n",
       " 23                         NaN     codeine_phosphate        NaN        NaN   \n",
       " 24                  nifedipine          _guaifenesin     -0.723     -0.076   \n",
       " 25       ezetimibe_simvastatin           fenofibrate     -0.609     -0.063   \n",
       " \n",
       "     Unnamed: 4  Unnamed: 5    Unnamed: 6 Unnamed: 7  \\\n",
       " 0           1%         99%           NaN        NaN   \n",
       " 1   posterior,  posterior,           50%    reverse   \n",
       " 2     negative    negative  posterior--u  causality   \n",
       " 3     controls    controls     nweighted       test   \n",
       " 4       -0.201       0.192        -0.185      0.089   \n",
       " 5          NaN         NaN           NaN        NaN   \n",
       " 6       -0.447       0.049        -0.029       0.58   \n",
       " 7       -0.674      -0.086        -0.023      0.991   \n",
       " 8          NaN         NaN           NaN        NaN   \n",
       " 9        -0.58      -0.011        -0.192      0.554   \n",
       " 10         NaN         NaN           NaN        NaN   \n",
       " 11      -0.683      -0.015        -0.154      0.684   \n",
       " 12         NaN         NaN           NaN        NaN   \n",
       " 13       -0.72      -0.172        -0.047      0.929   \n",
       " 14         NaN         NaN           NaN        NaN   \n",
       " 15       -0.33      -0.026        -0.064      0.679   \n",
       " 16      -0.352       0.417        -0.044      0.293   \n",
       " 17         NaN         NaN           NaN        NaN   \n",
       " 18       -0.52      -0.065        -0.134      0.918   \n",
       " 19      -0.121       0.164        -0.023      0.935   \n",
       " 20      -0.394       0.225        -0.254      0.466   \n",
       " 21         NaN         NaN           NaN        NaN   \n",
       " 22      -0.613      -0.218        -0.107      0.408   \n",
       " 23         NaN         NaN           NaN        NaN   \n",
       " 24      -0.477       0.103        -0.038      0.494   \n",
       " 25      -0.494        0.04        -0.033      0.527   \n",
       " \n",
       "                              Unnamed: 8 Unnamed: 9    reverse Unnamed: 10  \\\n",
       " 0                                    1%        99%  causality          1%   \n",
       " 1   posterior, 3  posterior, 3  test, 3        NaN        NaN  posterior,   \n",
       " 2                                 month      month      month          no   \n",
       " 3                               windows    windows    windows   censoring   \n",
       " 4                                -1.412     -0.466      0.056      -0.377   \n",
       " 5                                   NaN        NaN        NaN         NaN   \n",
       " 6                                   NaN        NaN        NaN      -0.679   \n",
       " 7                                -1.081     -0.032      0.973      -0.516   \n",
       " 8                                   NaN        NaN        NaN         NaN   \n",
       " 9                                -0.762     -0.169      0.299      -0.363   \n",
       " 10                                  NaN        NaN        NaN         NaN   \n",
       " 11                               -1.269     -0.355      0.845      -0.338   \n",
       " 12                                  NaN        NaN        NaN         NaN   \n",
       " 13                               -1.711     -0.499      0.991      -0.609   \n",
       " 14                                  NaN        NaN        NaN         NaN   \n",
       " 15                               -0.711     -0.074        NaN      -0.299   \n",
       " 16                               -1.422     -0.172      0.116      -0.641   \n",
       " 17                                  NaN        NaN        NaN         NaN   \n",
       " 18                               -0.999     -0.196      0.648      -0.675   \n",
       " 19                               -0.612     -0.158       0.41      -0.349   \n",
       " 20                               -1.098     -0.129      0.935      -0.514   \n",
       " 21                                  NaN        NaN        NaN         NaN   \n",
       " 22                               -1.077     -0.157      0.025      -0.512   \n",
       " 23                                  NaN        NaN        NaN         NaN   \n",
       " 24                               -1.121     -0.245      0.418      -0.439   \n",
       " 25                               -0.833     -0.092       0.29      -0.259   \n",
       " \n",
       "    Unnamed: 11      Unnamed: 12  \n",
       " 0          99%              NaN  \n",
       " 1   posterior,          reverse  \n",
       " 2           no  causality test,  \n",
       " 3    censoring     no censoring  \n",
       " 4       -0.095             0.84  \n",
       " 5          NaN              NaN  \n",
       " 6        -0.17            0.405  \n",
       " 7       -0.017            0.346  \n",
       " 8          NaN              NaN  \n",
       " 9        -0.03             0.02  \n",
       " 10         NaN              NaN  \n",
       " 11      -0.028            0.297  \n",
       " 12         NaN              NaN  \n",
       " 13       -0.06            0.416  \n",
       " 14         NaN              NaN  \n",
       " 15      -0.051              NaN  \n",
       " 16      -0.069            0.016  \n",
       " 17         NaN              NaN  \n",
       " 18      -0.143            0.634  \n",
       " 19      -0.083            0.283  \n",
       " 20      -0.016            0.282  \n",
       " 21         NaN              NaN  \n",
       " 22      -0.176            0.063  \n",
       " 23         NaN              NaN  \n",
       " 24      -0.022            0.631  \n",
       " 25      -0.072            0.818  ,\n",
       "                              Unnamed: 0  penicillin_v_potassi  Unnamed: 1  \\\n",
       " 0                             glyburide                    um      -0.802   \n",
       " 1  fexofenadine_hydrochloride  cefdinir                   NaN      -0.934   \n",
       " 2              budesonide_formoterol_fu    oseltamivir_phosph         NaN   \n",
       " 3                                marate                   ate      -1.062   \n",
       " 4                                   NaN    oseltamivir_phosph         NaN   \n",
       " 5                                niacin                   ate      -0.838   \n",
       " 6                                   NaN  penicillin_v_potassi         NaN   \n",
       " 7                             valsartan                    um      -0.513   \n",
       " 8                                   NaN   fluticasone_propion         NaN   \n",
       " 9                            omeprazole                   ate      -0.541   \n",
       " \n",
       "    Unnamed: 2  Unnamed: 3  Unnamed: 4  Unnamed: 5  Unnamed: 6  Unnamed: 7  \\\n",
       " 0      -0.059      -0.698      -0.151      -0.047       0.198      -0.902   \n",
       " 1      -0.049      -0.634       0.205      -0.038       0.555      -0.771   \n",
       " 2         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 3      -0.046      -0.761       0.000      -0.065       0.039         NaN   \n",
       " 4         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 5      -0.026      -0.296       0.250      -0.049       0.879         NaN   \n",
       " 6         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 7      -0.017      -0.436       0.065      -0.016       0.406      -0.763   \n",
       " 8         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 9      -0.012      -0.305      -0.055      -0.048       0.831      -0.783   \n",
       " \n",
       "    Unnamed: 8  Unnamed: 9  Unnamed: 10  Unnamed: 11  Unnamed: 12  \n",
       " 0      -0.038       0.184       -0.489       -0.096        0.984  \n",
       " 1      -0.025       0.406       -0.365       -0.084        0.460  \n",
       " 2         NaN         NaN          NaN          NaN          NaN  \n",
       " 3         NaN         NaN       -0.702       -0.084        0.082  \n",
       " 4         NaN         NaN          NaN          NaN          NaN  \n",
       " 5         NaN         NaN       -0.623       -0.177        0.242  \n",
       " 6         NaN         NaN          NaN          NaN          NaN  \n",
       " 7      -0.076       0.469       -0.289       -0.002        0.279  \n",
       " 8         NaN         NaN          NaN          NaN          NaN  \n",
       " 9      -0.180       0.212       -0.311       -0.006        0.312  ,\n",
       "                   Unnamed: 0               Unnamed: 1 Unnamed: 2 Unnamed: 3  \\\n",
       " 0                        NaN                      NaN        NaN        NaN   \n",
       " 1                        NaN                      NaN         1%        99%   \n",
       " 2                 Drug 1 (A)               Drug 2 (B)  posterior  posterior   \n",
       " 3                        NaN         acetaminophen_ox        NaN        NaN   \n",
       " 4                        NaN        ycodone_hydrochlo        NaN        NaN   \n",
       " 5   polyethylene_glycol_3350                     ride       0.18      0.723   \n",
       " 6                        NaN         acetaminophen_pr        NaN        NaN   \n",
       " 7                        NaN         opoxyphene_napsy        NaN        NaN   \n",
       " 8     tramadol_hydrochloride                     late      0.078      0.581   \n",
       " 9                        NaN         acetaminophen_pr        NaN        NaN   \n",
       " 10                       NaN         opoxyphene_napsy        NaN        NaN   \n",
       " 11                carvedilol                     late      0.008      0.471   \n",
       " 12                       NaN         acetaminophen_pr        NaN        NaN   \n",
       " 13  polyethylene_glycol_3350  opoxyphene_napsy  0.272        NaN      0.838   \n",
       " \n",
       "             1%         99%               Unnamed: 4  Unnamed: 5  \\\n",
       " 0   posterior,  posterior,             50%  reverse         NaN   \n",
       " 1     negative    negative  posterior--u  causality         NaN   \n",
       " 2     controls    controls          nweighted  test         NaN   \n",
       " 3          NaN         NaN                      NaN         NaN   \n",
       " 4          NaN         NaN                      NaN         NaN   \n",
       " 5       -0.241       0.331             1.072  0.045         NaN   \n",
       " 6          NaN         NaN                      NaN         NaN   \n",
       " 7          NaN         NaN                      NaN         NaN   \n",
       " 8        -0.17        0.26             0.592  0.528         NaN   \n",
       " 9          NaN         NaN                      NaN         NaN   \n",
       " 10         NaN         NaN                      NaN         NaN   \n",
       " 11      -0.213        0.34             0.519  0.142         NaN   \n",
       " 12         NaN         NaN                      NaN         NaN   \n",
       " 13      -0.015       0.417             0.937  0.003         NaN   \n",
       " \n",
       "                      1%  99%  Unnamed: 6 causality        1%.1       99%.1  \\\n",
       " 0   posterior,  posterior, 3         NaN   test, 3  posterior,  posterior,   \n",
       " 1             3 month  month         NaN     month          no          no   \n",
       " 2           windows  windows         NaN   windows   censoring   censoring   \n",
       " 3                        NaN         NaN       NaN         NaN         NaN   \n",
       " 4                        NaN         NaN       NaN         NaN         NaN   \n",
       " 5               0.233  0.937         NaN       NaN         NaN         NaN   \n",
       " 6                        NaN         NaN       NaN         NaN         NaN   \n",
       " 7                        NaN         NaN       NaN         NaN         NaN   \n",
       " 8               0.059  0.823         NaN       NaN         NaN         NaN   \n",
       " 9                        NaN         NaN       NaN         NaN         NaN   \n",
       " 10                       NaN         NaN       NaN         NaN         NaN   \n",
       " 11               0.09  0.534         NaN     0.066       0.224       0.457   \n",
       " 12                       NaN         NaN       NaN         NaN         NaN   \n",
       " 13              0.331  1.076         NaN       NaN         NaN         NaN   \n",
       " \n",
       "          Unnamed: 7  \n",
       " 0           reverse  \n",
       " 1   causality test,  \n",
       " 2      no censoring  \n",
       " 3               NaN  \n",
       " 4               NaN  \n",
       " 5               NaN  \n",
       " 6               NaN  \n",
       " 7               NaN  \n",
       " 8               NaN  \n",
       " 9               NaN  \n",
       " 10              NaN  \n",
       " 11            0.646  \n",
       " 12              NaN  \n",
       " 13              NaN  ,\n",
       "                                           Unnamed: 0    acetaminophen_pr  \\\n",
       " 0                                                NaN    opoxyphene_napsy   \n",
       " 1                                  divalproex_sodium                late   \n",
       " 2                                                NaN    acetaminophen_pr   \n",
       " 3                                                NaN    opoxyphene_napsy   \n",
       " 4                           tamsulosin_hydrochloride                late   \n",
       " 5                                                NaN    acetaminophen_pr   \n",
       " 6                                                NaN    opoxyphene_napsy   \n",
       " 7                           fluoxetine_hydrochloride                late   \n",
       " 8                                                NaN    acetaminophen_pr   \n",
       " 9                                                NaN    opoxyphene_napsy   \n",
       " 10                                       risperidone                late   \n",
       " 11                          acetaminophen_propoxyphe                 NaN   \n",
       " 12                                      ne_napsylate          alprazolam   \n",
       " 13  insulin_glargine__recombina  ciprofloxacin_hydro                 NaN   \n",
       " 14                                                nt            chloride   \n",
       " 15     amphetamine_salt_combina  ciprofloxacin_hydro                 NaN   \n",
       " 16                                              tion            chloride   \n",
       " 17                                        colchicine          furosemide   \n",
       " 18                        glucose_meter_test_control                 NaN   \n",
       " 19                                           _strips          furosemide   \n",
       " 20                                      lansoprazole          furosemide   \n",
       " 21                                               NaN  hydralazine_hydroc   \n",
       " 22                           clonidine_hydrochloride             hloride   \n",
       " 23                                        omeprazole        lansoprazole   \n",
       " 24                                         glyburide        levofloxacin   \n",
       " 25                       insulin_glargine__recombina                 NaN   \n",
       " 26                                                nt           lorazepam   \n",
       " 27                                        sucralfate           lorazepam   \n",
       " \n",
       "     Unnamed: 1  Unnamed: 2  Unnamed: 3  Unnamed: 4  Unnamed: 5  Unnamed: 6  \\\n",
       " 0          NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 1        0.200       0.878      -0.064       0.399       0.795       0.684   \n",
       " 2          NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 3          NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 4        0.163       0.450      -0.044       0.280       0.643       0.987   \n",
       " 5          NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 6          NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 7        0.070       0.579      -0.230       0.257       0.742       0.015   \n",
       " 8          NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 9          NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 10       0.301       1.183      -0.019       0.709       0.951       0.391   \n",
       " 11         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 12       0.020       0.560      -0.090       0.304       0.751       0.004   \n",
       " 13         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 14       0.024       0.328      -0.038       0.281       0.720       0.029   \n",
       " 15         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 16       0.086       0.742      -0.019       0.397       0.577       0.509   \n",
       " 17       0.131       0.945       0.092       0.763       0.722       0.007   \n",
       " 18         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 19       0.227       0.821       0.463       1.050       0.745       0.924   \n",
       " 20       0.103       0.758       0.094       0.869       0.553       0.001   \n",
       " 21         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 22       0.137       0.622       0.190       0.712       0.624       0.026   \n",
       " 23       0.058       0.681       0.011       0.406       0.906       0.053   \n",
       " 24       0.106       0.505       0.205       0.564       0.814       0.018   \n",
       " 25         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 26       0.041       0.462       0.073       0.475       1.109       0.076   \n",
       " 27       0.034       0.854       0.095       0.762       1.014       0.017   \n",
       " \n",
       "     Unnamed: 7  Unnamed: 8  Unnamed: 9  Unnamed: 10  Unnamed: 11  Unnamed: 12  \n",
       " 0          NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 1          NaN         NaN         NaN        0.137        0.649        0.322  \n",
       " 2          NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 3          NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 4        0.111       0.392         NaN        0.366        0.534          NaN  \n",
       " 5          NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 6          NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 7        0.086       0.758       0.005        0.253        0.551        0.199  \n",
       " 8          NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 9          NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 10         NaN         NaN         NaN        0.295        0.847        0.624  \n",
       " 11         NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 12       0.150       0.803         NaN          NaN          NaN          NaN  \n",
       " 13         NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 14       0.015       0.418         NaN          NaN          NaN          NaN  \n",
       " 15         NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 16       0.275       1.132         NaN          NaN          NaN          NaN  \n",
       " 17       0.047       0.890         NaN          NaN          NaN          NaN  \n",
       " 18         NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 19       0.060       0.863         NaN        0.258        0.631          NaN  \n",
       " 20       0.124       0.925         NaN          NaN          NaN          NaN  \n",
       " 21         NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 22       0.228       0.699         NaN        0.154        0.525          NaN  \n",
       " 23         NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 24       0.004       0.471         NaN          NaN          NaN          NaN  \n",
       " 25         NaN         NaN         NaN          NaN          NaN          NaN  \n",
       " 26       0.036       0.549         NaN          NaN          NaN          NaN  \n",
       " 27       0.415       1.237         NaN          NaN          NaN          NaN  ,\n",
       "                     risperidone            chloride  0.133  Unnamed: 0  1.012  \\\n",
       " 0                           NaN         nitrofurantoin_mon         NaN    NaN   \n",
       " 1                           NaN         ohydrate_nitrofura         NaN    NaN   \n",
       " 2                      ramipril            ntoin__m  0.085         NaN  0.859   \n",
       " 3              morphine_sulfate         ondansetron  0.001         NaN  0.848   \n",
       " 4                           NaN          ondansetron_hydro         NaN    NaN   \n",
       " 5              morphine_sulfate            chloride  0.386         NaN  0.923   \n",
       " 6                           NaN          ondansetron_hydro         NaN    NaN   \n",
       " 7                    sucralfate             chloride  0.31         NaN  1.064   \n",
       " 8   insulin_glargine__recombina                        NaN         NaN    NaN   \n",
       " 9                            nt  potassium_chloride  0.085         NaN  0.518   \n",
       " 10      clonidine_hydrochloride  potassium_chloride  0.071         NaN  0.662   \n",
       " 11                    glyburide   potassium_chloride  0.03         NaN  0.678   \n",
       " 12   pioglitazone_hydrochloride   potassium_chloride  0.02         NaN  0.559   \n",
       " 13             morphine_sulfate     warfarin_sodium  0.134         NaN  0.920   \n",
       " \n",
       "     -0.133  0.604  0.809  0.273  Unnamed: 1  Unnamed: 2  0.332  0.881  0.072  \n",
       " 0      NaN    NaN    NaN    NaN         NaN         NaN    NaN    NaN    NaN  \n",
       " 1      NaN    NaN    NaN    NaN         NaN         NaN    NaN    NaN    NaN  \n",
       " 2    0.121  0.825  0.707  0.009         NaN         NaN    NaN    NaN    NaN  \n",
       " 3   -0.158  0.533  1.041  0.601         NaN         NaN    NaN    NaN    NaN  \n",
       " 4      NaN    NaN    NaN    NaN         NaN         NaN    NaN    NaN    NaN  \n",
       " 5   -0.072  0.439  1.281  0.013       0.245       0.944    NaN    NaN    NaN  \n",
       " 6      NaN    NaN    NaN    NaN         NaN         NaN    NaN    NaN    NaN  \n",
       " 7    0.050  0.747  1.265  0.022       0.445       1.256    NaN    NaN    NaN  \n",
       " 8      NaN    NaN    NaN    NaN         NaN         NaN    NaN    NaN    NaN  \n",
       " 9    0.326  0.589  0.528  0.014       0.195       0.618    NaN    NaN    NaN  \n",
       " 10   0.390  0.724  0.617  0.002       0.106       0.651    NaN    NaN    NaN  \n",
       " 11   0.596  1.057  0.680  0.118       0.001       0.575    NaN    NaN    NaN  \n",
       " 12   0.369  0.821  0.836  0.005       0.015       0.530  0.048  0.363    NaN  \n",
       " 13   0.338  1.014  0.879  0.702         NaN         NaN  0.017  0.518  0.166  ,\n",
       " Empty DataFrame\n",
       " Columns: [No. of events (%)]\n",
       " Index: [],\n",
       "       Unnamed: 0        Without   With T1D    Crude   Model  Model 2  \\\n",
       " 0            NaN            T1D        NaN  OR (95%    1 OR       OR   \n",
       " 1            NaN            NaN        NaN      CI)    (95%     (95%   \n",
       " 2            NaN            NaN        NaN      NaN       a        b   \n",
       " 3            NaN            NaN        NaN      NaN     CI)      CI)   \n",
       " 4   Death ≤ 30 d     314 (0.01)      0 (0)       NA      NA       NA   \n",
       " 5     postpartum            NaN        NaN      NaN     NaN      NaN   \n",
       " 6   Preeclampsia  36,985 (1.57)        110    13.16   11.53    10.27   \n",
       " 7            NaN            NaN    (17.46)  (10.57–  (9.57–   (8.53–   \n",
       " 8            NaN            NaN        NaN   16.39)  13.90)    12.4)   \n",
       " 9      Eclampsia   1,755 (0.07)   8 (1.27)    16.60   17.36     15.6   \n",
       " 10           NaN            NaN        NaN   (7.95–  (8.71–   (7.81–   \n",
       " 11           NaN            NaN        NaN   34.68)  34.59)   31.15)   \n",
       " 12      Cesarean        781,843        386     2.86    1.89     1.85   \n",
       " 13      delivery        (33.27)    (61.27)   (2.38–  (1.76–   (1.72–   \n",
       " 14           NaN            NaN        NaN    3.43)   2.04)     2.0)   \n",
       " 15         Adult     999 (0.04)  14 (2.22)    53.48   53.99    38.34   \n",
       " 16   respiratory            NaN        NaN  (29.38–  (30.0–  (21.23–   \n",
       " 17      distress            NaN        NaN   97.36)   97.3)   69.21)   \n",
       " 18      syndrome            NaN        NaN      NaN     NaN      NaN   \n",
       " 19     Pulmonary     325 (0.01)   7 (1.11)    81.52   83.44    69.51   \n",
       " 20         edema            NaN        NaN  (38.40–  (39.6–  (32.81–   \n",
       " 21           NaN            NaN        NaN  173.08)    176)  147.25)   \n",
       " 22        Sepsis   5,853 (0.25)  22 (3.49)    14.21   14.25    11.04   \n",
       " 23           NaN            NaN        NaN   (8.89–  (9.13–   (7.12–   \n",
       " 24           NaN            NaN        NaN   22.69)  22.25)   17.11)   \n",
       " \n",
       "       P value  \n",
       " 0   (Model 2)  \n",
       " 1         NaN  \n",
       " 2         NaN  \n",
       " 3         NaN  \n",
       " 4         NaN  \n",
       " 5         NaN  \n",
       " 6    < 0.0001  \n",
       " 7         NaN  \n",
       " 8         NaN  \n",
       " 9    < 0.0001  \n",
       " 10        NaN  \n",
       " 11        NaN  \n",
       " 12   < 0.0001  \n",
       " 13        NaN  \n",
       " 14        NaN  \n",
       " 15   < 0.0001  \n",
       " 16        NaN  \n",
       " 17        NaN  \n",
       " 18        NaN  \n",
       " 19   < 0.0001  \n",
       " 20        NaN  \n",
       " 21        NaN  \n",
       " 22   < 0.0001  \n",
       " 23        NaN  \n",
       " 24        NaN  ,\n",
       "             Pregnancy- 53,917 (2.29)       132    11.16    9.51      8.34  \\\n",
       " 0              related           NaN   (20.95)   (9.07–  (8.02–    (7.04–   \n",
       " 1         hypertension           NaN       NaN   13.73)  11.26)     9.87)   \n",
       " 2            Puerperal  1,707 (0.07)  6 (0.95)    13.34   13.59     11.31   \n",
       " 3      cerebrovascular           NaN       NaN   (5.97–  (6.13–    (5.13–   \n",
       " 4            disorders           NaN       NaN   29.79)   30.1)    24.94)   \n",
       " 5          Acute renal    503 (0.02)  7 (1.11)    52.22   53.79     46.55   \n",
       " 6              failure           NaN       NaN  (22.61–  (23.3–   (20.21–   \n",
       " 7                  NaN           NaN       NaN  120.63)    124)   107.22)   \n",
       " 8    Internal injuries    966 (0.04)  2 (0.32)     3.74    3.78      3.13   \n",
       " 9           of thorax,           NaN       NaN   (0.53–  (0.53–    (0.45–   \n",
       " 10        abdomen, and           NaN       NaN   26.37)   26.8)    22.06)   \n",
       " 11              pelvis           NaN       NaN      NaN     NaN       NaN   \n",
       " 12             Cardiac    112 (0.00)  4 (0.63)   133.44  140.49    103.67   \n",
       " 13  arrest/ventricular           NaN       NaN  (40.42–  (41.9–   (30.83–   \n",
       " 14        fibrillation           NaN       NaN  440.54)    471)  3448.55)   \n",
       " 15               Acute    109 (0.00)  2 (0.32)    33.36   35.74     30.85   \n",
       " 16          myocardial           NaN       NaN   (4.66–  (5.01–    (4.27–   \n",
       " 17          infarction           NaN       NaN  238.63)    255)   222.68)   \n",
       " 18        Disseminated  1,541 (0.07)  2 (0.32)     2.56    2.57      2.31   \n",
       " 19       intravascular           NaN       NaN   (0.36–  (0.37–    (0.33–   \n",
       " 20         coagulation           NaN       NaN   18.00)  17.88)    16.32)   \n",
       " 21              Severe    300 (0.01)  2 (0.32)    12.70   12.62     12.07   \n",
       " 22          anesthesia           NaN       NaN   (1.78–  (1.78–    (1.73–   \n",
       " 23       complications           NaN       NaN   90.46)  89.64)    84.01)   \n",
       " \n",
       "     < 0.0001  \n",
       " 0        NaN  \n",
       " 1        NaN  \n",
       " 2   < 0.0001  \n",
       " 3        NaN  \n",
       " 4        NaN  \n",
       " 5   < 0.0001  \n",
       " 6        NaN  \n",
       " 7        NaN  \n",
       " 8    0.25209  \n",
       " 9        NaN  \n",
       " 10       NaN  \n",
       " 11       NaN  \n",
       " 12   0.00944  \n",
       " 13       NaN  \n",
       " 14       NaN  \n",
       " 15   0.00067  \n",
       " 16       NaN  \n",
       " 17       NaN  \n",
       " 18   0.40129  \n",
       " 19       NaN  \n",
       " 20       NaN  \n",
       " 21   0.01187  \n",
       " 22       NaN  \n",
       " 23       NaN  ,\n",
       "        Severe  63,345 (2.70)  25 (3.97)    1.47    1.46    1.33  0.15480\n",
       " 0  postpartum            NaN        NaN  (0.98–  (0.99–  (0.90–      NaN\n",
       " 1  hemorrhage            NaN        NaN   2.21)   2.16)   1.97)      NaN,\n",
       "          Yes  10,187 (72.2)  1,462 (72.8)\n",
       " 0        NaN            NaN           NaN\n",
       " 1         No  26,416 (27.8)  3,905 (27.2)\n",
       " 2        NaN            NaN           NaN\n",
       " 3  Education            NaN           NaN,\n",
       "       Unnamed: 0 Unnamed: 1  Unnamed: 2  \\\n",
       " 0            NaN        NaN         NaN   \n",
       " 1            NaN        NaN         NaN   \n",
       " 2  b Exposure  a          N         NaN   \n",
       " 3             GM     41,178         NaN   \n",
       " 4            TBV     41,178         NaN   \n",
       " 5            NaN        NaN         NaN   \n",
       " 6             HV     41,939         NaN   \n",
       " 7            NaN        NaN         NaN   \n",
       " 8            WMH     39,870         NaN   \n",
       " 9           CTAD     41,939         NaN   \n",
       " \n",
       "                Demographics- Fully Adjusted  Unnamed: 3 Unnamed: 4  \n",
       " 0                     d Adjusted Base Model         NaN        NaN  \n",
       " 1                                   c Model         NaN        NaN  \n",
       " 2           HR (95% CI) p-value HR (95% CI)         NaN    p-value  \n",
       " 3  0.34 (0.28-0.41) <0.001 0.36 (0.29-0.44)         NaN     <0.001  \n",
       " 4  0.49 (0.41-0.58) <0.001 0.50 (0.42-0.60)         NaN     <0.001  \n",
       " 5                                       NaN         NaN        NaN  \n",
       " 6  0.41 (0.35-0.49) <0.001 0.44 (0.36-0.54)         NaN     <0.001  \n",
       " 7                                       NaN         NaN        NaN  \n",
       " 8  1.26 (1.11-1.42) <0.001 1.27 (1.11-1.45)         NaN     <0.001  \n",
       " 9  0.51 (0.42-0.63) <0.001 0.52 (0.42-0.65)         NaN     <0.001  ,\n",
       "      Unnamed: 0 Unnamed: 1  Unnamed: 2 Unnamed: 3  \\\n",
       " 0           NaN        NaN         NaN        NaN   \n",
       " 1           NaN        NaN         NaN        NaN   \n",
       " 2  b Outcome  a          N         NaN   Estimate   \n",
       " 3            GM     41,378         NaN       -452   \n",
       " 4           TBV     41,378         NaN       -293   \n",
       " 5            HV     42,036         NaN        -23   \n",
       " 6           WMH     40,119         NaN        216   \n",
       " 7          CTAD     42,036         NaN     -0.004   \n",
       " \n",
       "                      Demographics- Fully Adjusted  Unnamed: 4 Unnamed: 5  \n",
       " 0                            dAdjusted Base Model         NaN        NaN  \n",
       " 1                                          cModel         NaN        NaN  \n",
       " 2                  95% CI p-value Estimate 95% CI         NaN    p-value  \n",
       " 3            -1146 to 241 0.201 -350 -1056 to 355         NaN      0.330  \n",
       " 4            -1401 to 815 0.604 -376 -1510 to 758         NaN      0.515  \n",
       " 5                   -40 to -6 0.008 -19 -36 to -1         NaN      0.037  \n",
       " 6                   39 to 392 0.017 178 -1 to 357         NaN      0.051  \n",
       " 7  -0.007 to -0.001 0.007 -0.004 -0.007 to -0.000         NaN      0.026  ,\n",
       "   Speed ~ a1*HIIT + c11*6MWDbaseline + c12*FM-LLbaseline  [1]\n",
       " 0  Heart rate ~ a2*HIIT + c21*6MWDbaseline + c22*...      [2]\n",
       " 1  Lactate ~ a3*HIIT + c31*6MWDbaseline + c32*FM-...      [3]\n",
       " 2  Step count ~ a4*HIIT + c41*6MWDbaseline + c42*...      [4],\n",
       "      Unnamed: 0                                         Unnamed: 1\n",
       " 0           NaN         Clinical trial analysis Mediation analysis\n",
       " 1           NaN                                                NaN\n",
       " 2           NaN                                                a b\n",
       " 3    Conceptual                                           Mediator\n",
       " 4          path                                                NaN\n",
       " 5       diagram            c'Treatment c Outcome Treatment Outcome\n",
       " 6           NaN                                       a Training b\n",
       " 7       Example                                              speed\n",
       " 8          path                                                NaN\n",
       " 9       diagram                           HIIT c 6MWD HIIT c' 6MWD\n",
       " 10          NaN                      vs. MAT change vs. MAT change\n",
       " 11   Regression                                     Speed ~ a*HIIT\n",
       " 12  equation(s)  6MWDchange ~ c*HIIT 6MWDchange ~ b*Speed + c’*...\n",
       " 13  Estimate of                                            c a x b\n",
       " 14      primary  Total effect of HIIT on 6MWDchange Effect of H...\n",
       " 15     interest                   occurring through training speed,\n",
       "    Training parameters\\ra1\\rSpeedb1\\ra2\\rHeart rateb2\\ra3\\rLactateb3\\ra4\\rStepsb4\\rHIIT\\rc'6MWD\\rvs. MATchange  \\\n",
       " 0                                                NaN                                                             \n",
       " 1                                                NaN                                                             \n",
       " \n",
       "    Unnamed: 0  \n",
       " 0         NaN  \n",
       " 1         NaN  ,\n",
       "    Training parameters\\ra1\\rSpeedb1\\ra2\\rHeart rateb2\\ra3\\rLactateb3\\ra4\\rStepsb4\\rHIIT\\rc'6MWD\\rvs. MATchange\n",
       " 0                                                NaN                                                          ,\n",
       "    Training parameters\\ra1\\rSpeedb1\\ra2\\rHeart rateb2\\ra3\\rLactateb3\\ra4\\rStepsb4\\rHIIT\\rc'6MWD\\rvs. MATchange\n",
       " 0                                                NaN                                                          ,\n",
       "    Training parameters\\ra1\\rSpeedb1\\ra2\\rHeart rateb2\\ra3\\rLactateb3\\ra4\\rStepsb4\\rHIIT\\rc'6MWD\\rvs. MATchange\n",
       " 0                                                NaN                                                          ,\n",
       "   Training parameters\\ra1\\rSpeedb1\\ra2\\rHeart rateb2\\ra3\\rLactateb3\\ra4\\rStepsb4\\rHIIT\\rc'6MWD\\rvs. MATchange  \\\n",
       " 0                                                NaN                                                            \n",
       " 1                                                NaN                                                            \n",
       " 2                                                NaN                                                            \n",
       " 3                                                NaN                                                            \n",
       " 4                                                NaN                                                            \n",
       " 5                                                NaN                                                            \n",
       " 6                                                NaN                                                            \n",
       " 7  Mediated (indirect) effects\\rVia speed:a1 x b1...                                                            \n",
       " \n",
       "    Training parameters\\r.73*.72*Speed\\r.60*\\rHeart rate-.05\\r.31\\rLactate.10\\r-.35\\rSteps.35\\rHIIT\\r-.106MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia speed:.73x  .72  =   .53*\\rVia heart rate:.60  x -.05  =  -.03\\rVia lactate:.31  x  .10  =   .03\\rVia steps:-.35  x  .35  =  -.12  \\\n",
       " 0                                                NaN                                                                                                                                                                                                                                              \n",
       " 1                                                NaN                                                                                                                                                                                                                                              \n",
       " 2                                                NaN                                                                                                                                                                                                                                              \n",
       " 3                                                NaN                                                                                                                                                                                                                                              \n",
       " 4                                                NaN                                                                                                                                                                                                                                              \n",
       " 5                                                NaN                                                                                                                                                                                                                                              \n",
       " 6                                                NaN                                                                                                                                                                                                                                              \n",
       " 7                                                NaN                                                                                                                                                                                                                                              \n",
       " \n",
       "    Unnamed: 0  Unnamed: 1  Unnamed: 2  Unnamed: 3  \n",
       " 0         NaN         NaN         NaN         NaN  \n",
       " 1         NaN         NaN         NaN         NaN  \n",
       " 2         NaN         NaN         NaN         NaN  \n",
       " 3         NaN         NaN         NaN         NaN  \n",
       " 4         NaN         NaN         NaN         NaN  \n",
       " 5         NaN         NaN         NaN         NaN  \n",
       " 6         NaN         NaN         NaN         NaN  \n",
       " 7         NaN         NaN         NaN         NaN  ,\n",
       "    Training parameters\\ra1\\rSpeedb1\\ra2\\rHeart rateb2\\ra3\\rLactateb3\\ra4\\rStepsb4\\rHIIT\\rc'6MWD\\rvs. MATchange\n",
       " 0                                                NaN                                                          ,\n",
       "    Training parameters\\ra1\\rSpeedb1\\ra2\\rHeart rateb2\\ra3\\rLactateb3\\ra4\\rStepsb4\\rHIIT\\rc'6MWD\\rvs. MATchange\n",
       " 0                                                NaN                                                          ,\n",
       "    Training parameters\\ra1\\rSpeedb1\\ra2\\rHeart rateb2\\ra3\\rLactateb3\\ra4\\rStepsb4\\rHIIT\\rc'6MWD\\rvs. MATchange\n",
       " 0                                                NaN                                                          ,\n",
       "    Training parameters\\r.73*.72*Speed\\r.60*\\rHeart rate-.05\\r.31\\rLactate.10\\r-.35\\rSteps.35\\rHIIT\\r-.106MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia speed:.73x  .72  =   .53*\\rVia heart rate:.60  x -.05  =  -.03\\rVia lactate:.31  x  .10  =   .03\\rVia steps:-.35  x  .35  =  -.12\n",
       " 0                                                NaN                                                                                                                                                                                                                                           \n",
       " 1                                                NaN                                                                                                                                                                                                                                           ,\n",
       "    Training parameters\\r.73*.72*Speed\\r.60*\\rHeart rate-.05\\r.31\\rLactate.10\\r-.35\\rSteps.35\\rHIIT\\r-.106MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia speed:.73x  .72  =   .53*\\rVia heart rate:.60  x -.05  =  -.03\\rVia lactate:.31  x  .10  =   .03\\rVia steps:-.35  x  .35  =  -.12\n",
       " 0                                                NaN                                                                                                                                                                                                                                           ,\n",
       "    Training parameters\\r.73*.72*Speed\\r.60*\\rHeart rate-.05\\r.31\\rLactate.10\\r-.35\\rSteps.35\\rHIIT\\r-.106MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia speed:.73x  .72  =   .53*\\rVia heart rate:.60  x -.05  =  -.03\\rVia lactate:.31  x  .10  =   .03\\rVia steps:-.35  x  .35  =  -.12\n",
       " 0                                                NaN                                                                                                                                                                                                                                           ,\n",
       "    Training parameters\\r.73*.72*Speed\\r.60*\\rHeart rate-.05\\r.31\\rLactate.10\\r-.35\\rSteps.35\\rHIIT\\r-.106MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia speed:.73x  .72  =   .53*\\rVia heart rate:.60  x -.05  =  -.03\\rVia lactate:.31  x  .10  =   .03\\rVia steps:-.35  x  .35  =  -.12  \\\n",
       " 0                                                NaN                                                                                                                                                                                                                                              \n",
       " 1                                                NaN                                                                                                                                                                                                                                              \n",
       " \n",
       "    Unnamed: 0  \n",
       " 0         NaN  \n",
       " 1         NaN  ,\n",
       "    Training parameters\\r.73*.72*Speed\\r.60*\\rHeart rate-.05\\r.31\\rLactate.10\\r-.35\\rSteps.35\\rHIIT\\r-.106MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia speed:.73x  .72  =   .53*\\rVia heart rate:.60  x -.05  =  -.03\\rVia lactate:.31  x  .10  =   .03\\rVia steps:-.35  x  .35  =  -.12\n",
       " 0                                                NaN                                                                                                                                                                                                                                           ,\n",
       "    Training parameters\\r.73*.72*Speed\\r.60*\\rHeart rate-.05\\r.31\\rLactate.10\\r-.35\\rSteps.35\\rHIIT\\r-.106MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia speed:.73x  .72  =   .53*\\rVia heart rate:.60  x -.05  =  -.03\\rVia lactate:.31  x  .10  =   .03\\rVia steps:-.35  x  .35  =  -.12\n",
       " 0                                                NaN                                                                                                                                                                                                                                           \n",
       " 1                                                NaN                                                                                                                                                                                                                                           ,\n",
       "    a6Gait speed\\rb6\\rchange\\rVentilatory\\ra7b7threshold\\rchange\\rHIIT\\rc'6MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia gait change:a6 x b6\\rVia aerobic change:a7 x b7  \\\n",
       " 0                                                NaN                                                                                                                             \n",
       " \n",
       "    Unnamed: 0  \n",
       " 0         NaN  ,\n",
       "   a6Gait speed\\rb6\\rchange\\rVentilatory\\ra7b7threshold\\rchange\\rHIIT\\rc'6MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia gait change:a6 x b6\\rVia aerobic change:a7 x b7  \\\n",
       " 0                                                NaN                                                                                                                            \n",
       " 1                                                NaN                                                                                                                            \n",
       " 2                                                NaN                                                                                                                            \n",
       " 3                                                NaN                                                                                                                            \n",
       " 4                                                NaN                                                                                                                            \n",
       " 5                                                NaN                                                                                                                            \n",
       " 6                                                NaN                                                                                                                            \n",
       " 7                                                NaN                                                                                                                            \n",
       " 8  Mediated (indirect) effects\\rVia gait change:....                                                                                                                            \n",
       " \n",
       "    .41*Gait speed\\r.81*\\rchange\\rVentilatory\\r.06*.12*threshold\\rchange\\rHIIT\\r-.056MWD\\rvs. MAT\\rchange\\rMediated (indirect) effects\\rVia gait change:.41 x .81 = .33*\\rVia aerobic change:.06 x .12 = .01  \\\n",
       " 0                                                NaN                                                                                                                                                          \n",
       " 1                                                NaN                                                                                                                                                          \n",
       " 2                                                NaN                                                                                                                                                          \n",
       " 3                                                NaN                                                                                                                                                          \n",
       " 4                                                NaN                                                                                                                                                          \n",
       " 5                                                NaN                                                                                                                                                          \n",
       " 6                                                NaN                                                                                                                                                          \n",
       " 7                                                NaN                                                                                                                                                          \n",
       " 8                                                NaN                                                                                                                                                          \n",
       " \n",
       "    Unnamed: 0  Unnamed: 1  Unnamed: 2  Unnamed: 3  Unnamed: 4  Unnamed: 5  \\\n",
       " 0         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 1         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 2         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 3         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 4         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 5         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 6         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 7         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 8         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " \n",
       "    Unnamed: 6  Unnamed: 7  Unnamed: 8  Unnamed: 9  Unnamed: 10  Unnamed: 11  \\\n",
       " 0         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 1         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 2         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 3         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 4         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 5         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 6         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 7         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 8         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " \n",
       "    Unnamed: 12  Unnamed: 13  Unnamed: 14  Unnamed: 15  Unnamed: 16  \n",
       " 0          NaN          NaN          NaN          NaN          NaN  \n",
       " 1          NaN          NaN          NaN          NaN          NaN  \n",
       " 2          NaN          NaN          NaN          NaN          NaN  \n",
       " 3          NaN          NaN          NaN          NaN          NaN  \n",
       " 4          NaN          NaN          NaN          NaN          NaN  \n",
       " 5          NaN          NaN          NaN          NaN          NaN  \n",
       " 6          NaN          NaN          NaN          NaN          NaN  \n",
       " 7          NaN          NaN          NaN          NaN          NaN  \n",
       " 8          NaN          NaN          NaN          NaN          NaN  ,\n",
       "    a6Gait speed\\rb6\\rchange\\rVentilatory\\ra7b7threshold\\rchange\\rHIIT\\rc'6MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia gait change:a6 x b6\\rVia aerobic change:a7 x b7\n",
       " 0                                                NaN                                                                                                                          ,\n",
       "    a6Gait speed\\rb6\\rchange\\rVentilatory\\ra7b7threshold\\rchange\\rHIIT\\rc'6MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia gait change:a6 x b6\\rVia aerobic change:a7 x b7\n",
       " 0                                                NaN                                                                                                                          ,\n",
       "    a6Gait speed\\rb6\\rchange\\rVentilatory\\ra7b7threshold\\rchange\\rHIIT\\rc'6MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia gait change:a6 x b6\\rVia aerobic change:a7 x b7\n",
       " 0                                                NaN                                                                                                                          ,\n",
       "    a6Gait speed\\rb6\\rchange\\rVentilatory\\ra7b7threshold\\rchange\\rHIIT\\rc'6MWD\\rvs. MATchange\\rMediated (indirect) effects\\rVia gait change:a6 x b6\\rVia aerobic change:a7 x b7\n",
       " 0                                                NaN                                                                                                                          ,\n",
       "    .41*Gait speed\\r.81*\\rchange\\rVentilatory\\r.06*.12*threshold\\rchange\\rHIIT\\r-.056MWD\\rvs. MAT\\rchange\\rMediated (indirect) effects\\rVia gait change:.41 x .81 = .33*\\rVia aerobic change:.06 x .12 = .01\n",
       " 0                                                NaN                                                                                                                                                       ,\n",
       "    .41*Gait speed\\r.81*\\rchange\\rVentilatory\\r.06*.12*threshold\\rchange\\rHIIT\\r-.056MWD\\rvs. MAT\\rchange\\rMediated (indirect) effects\\rVia gait change:.41 x .81 = .33*\\rVia aerobic change:.06 x .12 = .01  \\\n",
       " 0                                                NaN                                                                                                                                                          \n",
       " \n",
       "    Unnamed: 0  Unnamed: 1  Unnamed: 2  Unnamed: 3  Unnamed: 4  Unnamed: 5  \\\n",
       " 0         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " \n",
       "    Unnamed: 6  Unnamed: 7  Unnamed: 8  Unnamed: 9  Unnamed: 10  Unnamed: 11  \\\n",
       " 0         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " \n",
       "    Unnamed: 12  Unnamed: 13  Unnamed: 14  Unnamed: 15  \n",
       " 0          NaN          NaN          NaN          NaN  ,\n",
       "    .41*Gait speed\\r.81*\\rchange\\rVentilatory\\r.06*.12*threshold\\rchange\\rHIIT\\r-.056MWD\\rvs. MAT\\rchange\\rMediated (indirect) effects\\rVia gait change:.41 x .81 = .33*\\rVia aerobic change:.06 x .12 = .01\n",
       " 0                                                NaN                                                                                                                                                       ,\n",
       "    .41*Gait speed\\r.81*\\rchange\\rVentilatory\\r.06*.12*threshold\\rchange\\rHIIT\\r-.056MWD\\rvs. MAT\\rchange\\rMediated (indirect) effects\\rVia gait change:.41 x .81 = .33*\\rVia aerobic change:.06 x .12 = .01\n",
       " 0                                                NaN                                                                                                                                                       ,\n",
       "    .41*Gait speed\\r.81*\\rchange\\rVentilatory\\r.06*.12*threshold\\rchange\\rHIIT\\r-.056MWD\\rvs. MAT\\rchange\\rMediated (indirect) effects\\rVia gait change:.41 x .81 = .33*\\rVia aerobic change:.06 x .12 = .01\n",
       " 0                                                NaN                                                                                                                                                       ,\n",
       "    .41*Gait speed\\r.81*\\rchange\\rVentilatory\\r.06*.12*threshold\\rchange\\rHIIT\\r-.056MWD\\rvs. MAT\\rchange\\rMediated (indirect) effects\\rVia gait change:.41 x .81 = .33*\\rVia aerobic change:.06 x .12 = .01  \\\n",
       " 0                                                NaN                                                                                                                                                          \n",
       " 1                                                NaN                                                                                                                                                          \n",
       " 2                                                NaN                                                                                                                                                          \n",
       " 3                                                NaN                                                                                                                                                          \n",
       " 4                                                NaN                                                                                                                                                          \n",
       " 5                                                NaN                                                                                                                                                          \n",
       " 6                                                NaN                                                                                                                                                          \n",
       " \n",
       "    Unnamed: 0  Unnamed: 1  Unnamed: 2  Unnamed: 3  Unnamed: 4  Unnamed: 5  \\\n",
       " 0         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 1         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 2         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 3         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 4         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 5         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " 6         NaN         NaN         NaN         NaN         NaN         NaN   \n",
       " \n",
       "    Unnamed: 6  Unnamed: 7  Unnamed: 8  Unnamed: 9  Unnamed: 10  Unnamed: 11  \\\n",
       " 0         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 1         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 2         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 3         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 4         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 5         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " 6         NaN         NaN         NaN         NaN          NaN          NaN   \n",
       " \n",
       "    Unnamed: 12  Unnamed: 13  Unnamed: 14  Unnamed: 15  \n",
       " 0          NaN          NaN          NaN          NaN  \n",
       " 1          NaN          NaN          NaN          NaN  \n",
       " 2          NaN          NaN          NaN          NaN  \n",
       " 3          NaN          NaN          NaN          NaN  \n",
       " 4          NaN          NaN          NaN          NaN  \n",
       " 5          NaN          NaN          NaN          NaN  \n",
       " 6          NaN          NaN          NaN          NaN  ,\n",
       "    .41*Gait speed\\r.81*\\rchange\\rVentilatory\\r.06*.12*threshold\\rchange\\rHIIT\\r-.056MWD\\rvs. MAT\\rchange\\rMediated (indirect) effects\\rVia gait change:.41 x .81 = .33*\\rVia aerobic change:.06 x .12 = .01  \\\n",
       " 0                                                NaN                                                                                                                                                          \n",
       " 1                                                NaN                                                                                                                                                          \n",
       " \n",
       "    Unnamed: 0  Unnamed: 1  \n",
       " 0         NaN         NaN  \n",
       " 1         NaN         NaN  ,\n",
       "                Baseline self-selected gait speed, m/s  0.65 (0.29)  \\\n",
       " 0   Baseline self-selected gait speed, % normative...  50.5 (23.3)   \n",
       " 1                    Baseline fastest gait speed, m/s  0.89 (0.47)   \n",
       " 2                                    Baseline 6MWD, m    248 (136)   \n",
       " 3                          Baseline 6MWD, % predicted  48.5 (26.3)   \n",
       " 4       Baseline ventilatory threshold VO2, mL/kg/min   12.1 (3.9)   \n",
       " 5   Baseline ventilatory threshold VO2, % normativ...  93.1 (24.4)   \n",
       " 6                        Baseline VO2-peak, mL/kg/min   14.3 (4.4)   \n",
       " 7                Baseline VO2-peak, % normative value  60.4 (15.9)   \n",
       " 8                                 Training parameters          NaN   \n",
       " 9      Training speed relative to self-selected, m/sa  0.52 (0.23)   \n",
       " 10  Training heart rate relative to standing rest,...  61.9 (13.0)   \n",
       " 11  Training blood lactate elevation >2 mmol/L, mm...    1.3 (1.3)   \n",
       " 12                 Training step count, steps/session   2801 (820)   \n",
       " 13                                   Outcome changesd          NaN   \n",
       " 14                                     6MWD change, m      70 (50)   \n",
       " 15                     Fastest gait speed change, m/s  0.29 (0.20)   \n",
       " 16               Self-selected gait speed change, m/s  0.20 (0.14)   \n",
       " \n",
       "     0.62 (0.33)   0.7454  \n",
       " 0   47.3 (25.1)   0.6261  \n",
       " 1   0.81 (0.44)   0.5341  \n",
       " 2     230 (130)   0.6147  \n",
       " 3   44.3 (26.8)   0.5558  \n",
       " 4    11.6 (3.9)   0.5926  \n",
       " 5   82.5 (26.2)   0.1241  \n",
       " 6    14.0 (4.8)   0.7852  \n",
       " 7   55.1 (19.3)   0.2737  \n",
       " 8           NaN      NaN  \n",
       " 9   0.07 (0.16)  <0.0001  \n",
       " 10   45.9 (8.3)  <0.0001  \n",
       " 11    0.6 (0.8)   0.0250  \n",
       " 12  3456 (1393)   0.0392  \n",
       " 13          NaN      NaN  \n",
       " 14      36 (55)   0.0203  \n",
       " 15  0.10 (0.20)   0.0011  \n",
       " 16  0.08 (0.14)   0.0038  ,\n",
       "   Table 4. Model fit and multicollinearity measures for all models Unnamed: 0  \\\n",
       " 0                           c2 p c /df  2 CFI  RMSEA                     SRMR   \n",
       " 1                                              value                      NaN   \n",
       " 2                                                NaN                      NaN   \n",
       " 3       Desirable values >.05 <2-5 >.90-.95 <.06-.10                 <.05-.08   \n",
       " 4           Mediating effects of training parameters                      NaN   \n",
       " 5                               1.00 0.001 1.00 0.00                    0.001   \n",
       " \n",
       "   Unnamed: 1     Unnamed: 2  \n",
       " 0        Max  Max condition  \n",
       " 1        VIF            NaN  \n",
       " 2        NaN          index  \n",
       " 3      <5-10         <10-30  \n",
       " 4        NaN            NaN  \n",
       " 5        3.8            4.5  ,\n",
       "                             Unnamed: 0          Yes           No\n",
       " 0                            Variables          NaN          NaN\n",
       " 1                                  NaN        n (%)        n (%)\n",
       " 2                            Knowledge          NaN          NaN\n",
       " 3                        Time tracking  252 (75.2%)   83 (24.8%)\n",
       " 4                  Over usage warnings  249 (74.3%)   86 (25.7%)\n",
       " 5                          App locking  232 (69.3%)  103 (30.7%)\n",
       " 6                           Focus Mode  186 (55.5%)  149 (44.5%)\n",
       " 7                        Phone locking  204 (60.9%)  131 (39.1%)\n",
       " 8                    Digital Wellbeing          NaN          NaN\n",
       " 9                             DND Mode  290 (86.6%)   45 (13.4%)\n",
       " 10                            Features          NaN          NaN\n",
       " 11                   Blue light filter  244 (72.8%)   91 (27.2%)\n",
       " 12                     Gray Scale Mode    164 (49%)    171 (51%)\n",
       " 13                Features in Facebook  148 (44.2%)  187 (55.8%)\n",
       " 14                 Features in YouTube    191 (57%)    144 (43%)\n",
       " 15               Features in Instagram  178 (53.1%)  157 (46.9%)\n",
       " 16                           Attitudes          NaN          NaN\n",
       " 17                    Reduce aggregate          NaN          NaN\n",
       " 18                                 NaN    298 (89%)     37 (11%)\n",
       " 19                         screen time          NaN          NaN\n",
       " 20                  Help focus on work          NaN          NaN\n",
       " 21                     and increase in  285 (85.1%)   50 (14.9%)\n",
       " 22                   Digital Wellbeing          NaN          NaN\n",
       " 23                        productivity          NaN          NaN\n",
       " 24                    Features help to          NaN          NaN\n",
       " 25                      Prevent Screen          NaN          NaN\n",
       " 26                                 NaN  273 (81.5%)   62 (18.5%)\n",
       " 27                           Addiction          NaN          NaN\n",
       " 28                     Overcome Screen          NaN          NaN\n",
       " 29                                 NaN  263 (78.5%)   72 (21.5%)\n",
       " 30                           Addiction          NaN          NaN\n",
       " 31                    Locking Features          NaN          NaN\n",
       " 32                      should be made  229 (68.4%)  106 (31.6%)\n",
       " 33                            stricter          NaN          NaN\n",
       " 34                  Adding more Mental          NaN          NaN\n",
       " 35                                 NaN  269 (80.3%)   66 (19.7%)\n",
       " 36                 well-being features          NaN          NaN\n",
       " 37                     Adding tools to          NaN          NaN\n",
       " 38                monitor the level of          NaN          NaN\n",
       " 39                     Suggestions for    305 (91%)    30 (9.0%)\n",
       " 40                              screen          NaN          NaN\n",
       " 41                       improving the          NaN          NaN\n",
       " 42                dependency/addiction          NaN          NaN\n",
       " 43                   digital wellbeing          NaN          NaN\n",
       " 44                     Adding Helpline          NaN          NaN\n",
       " 45                            features          NaN          NaN\n",
       " 46               numbers/links to seek  206 (61.5%)  129 (38.5%)\n",
       " 47                           treatment          NaN          NaN\n",
       " 48                          Creating a          NaN          NaN\n",
       " 49                    standardized app          NaN          NaN\n",
       " 50                  similar to Aarogya  217 (64.8%)  118 (35.2%)\n",
       " 51                 Setu for purpose of          NaN          NaN\n",
       " 52                  digital well being          NaN          NaN\n",
       " 53                           Practices          NaN          NaN\n",
       " 54                    Avoiding devices          NaN          NaN\n",
       " 55  Digital Hygiene upon waking up and  210 (62.7%)  125 (37.3%)\n",
       " 56                     before sleeping          NaN          NaN,\n",
       "        Spending time with   Unnamed: 0   Unnamed: 1\n",
       " 0                     NaN  254 (75.8%)   81 (24.2%)\n",
       " 1                  nature          NaN          NaN\n",
       " 2      Spending time with          NaN          NaN\n",
       " 3                     NaN  308 (91.9%)    27 (8.1%)\n",
       " 4    your family/ friends          NaN          NaN\n",
       " 5     Practicing a hobby/          NaN          NaN\n",
       " 6                     NaN  271 (80.9%)   64 (19.1%)\n",
       " 7                   sport          NaN          NaN\n",
       " 8   Practicing meditation  195 (58.2%)  140 (41.8%)\n",
       " 9      Self-care routines  233 (69.6%)  102 (30.4%)\n",
       " 10     Reading / Studying  279 (83.3%)   56 (16.7%)\n",
       " 11     Practicing Digital          NaN          NaN\n",
       " 12                    NaN  145 (43.3%)  190 (56.7%)\n",
       " 13                  Detox          NaN          NaN,\n",
       "          Feature        Never      Rarely   Sometimes       Often      Always\n",
       " 0           Time   75 (22.4%)  46 (13.7%)  34 (10.1%)  35 (10.4%)  29 (13.3%)\n",
       " 1       Tracking          NaN         NaN         NaN         NaN         NaN\n",
       " 2     Over Usage   71 (21.2%)  47 (14.0%)  41 (12.2%)  35 (10.4%)   25 (7.5%)\n",
       " 3       Warnings          NaN         NaN         NaN         NaN         NaN\n",
       " 4    App Locking  104 (31.0%)  46 (13.7%)   31 (9.3%)   23 (6.9%)   15 (4.5%)\n",
       " 5     Focus Mode   96 (28.7%)  46 (13.7%)   33 (9.9%)   25 (7.5%)   19 (5.7%)\n",
       " 6          Phone  113 (33.7%)  37 (11.0%)   30 (9.0%)   25 (7.5%)   14 (4.2%)\n",
       " 7   Locking/ Zen          NaN         NaN         NaN         NaN         NaN\n",
       " 8           Mode          NaN         NaN         NaN         NaN         NaN\n",
       " 9       DND Mode   69 (20.6%)  49 (14.6%)  46 (13.7%)   28 (8.4%)   27 (8.1%)\n",
       " 10      Parental  149 (44.5%)   26 (7.8%)   20 (6.0%)   14 (4.2%)   10 (3.0%)\n",
       " 11       Control          NaN         NaN         NaN         NaN         NaN\n",
       " 12    Blue Light   64 (19.1%)   32 (9.6%)  40 (11.9%)  34 (10.1%)  49 (14.6%)\n",
       " 13        Filter          NaN         NaN         NaN         NaN         NaN\n",
       " 14    Grey Scale  114 (34.0%)  41 (12.2%)   32 (9.6%)   16 (4.8%)   16 (4.8%)\n",
       " 15          Mode          NaN         NaN         NaN         NaN         NaN,\n",
       "    Unnamed: 0 Unnamed: 1 Unnamed: 2 Unnamed: 3 Unnamed: 4 Unnamed: 5  \\\n",
       " 0         NaN     Use of        NaN        NaN        NaN        NaN   \n",
       " 1         NaN    Digital        NaN        NaN   Standard        NaN   \n",
       " 2    Variable        NaN      n (%)       Mean        NaN          t   \n",
       " 3         NaN  Wellbeing        NaN        NaN  Deviation        NaN   \n",
       " 4         NaN   Features        NaN        NaN        NaN        NaN   \n",
       " 5         NaN        NaN        NaN        NaN        NaN        NaN   \n",
       " 6     Average        NaN        219        NaN        NaN        NaN   \n",
       " 7         NaN        Yes        NaN       4.33      2.412        NaN   \n",
       " 8      Screen        NaN    (65.3%)        NaN        NaN        NaN   \n",
       " 9    time per        NaN        NaN        NaN        NaN        NaN   \n",
       " 10     day in        NaN        NaN        NaN        NaN        NaN   \n",
       " 11        NaN        NaN        NaN        NaN        NaN      1.767   \n",
       " 12      hours        NaN        116        NaN        NaN        NaN   \n",
       " 13        NaN         No        NaN       3.84      2.332        NaN   \n",
       " 14  excluding        NaN    (34.7%)        NaN        NaN        NaN   \n",
       " 15       work        NaN        NaN        NaN        NaN        NaN   \n",
       " 16      hours        NaN        NaN        NaN        NaN        NaN   \n",
       " 17        NaN        NaN        219        NaN        NaN        NaN   \n",
       " 18        NaN        Yes        NaN      29.87     11.918        NaN   \n",
       " 19  Addiction        NaN    (65.3%)        NaN        NaN        NaN   \n",
       " 20        NaN        NaN        NaN        NaN        NaN      1.550   \n",
       " 21     Scores        NaN        116        NaN        NaN        NaN   \n",
       " 22        NaN         No        NaN      27.77     11.572        NaN   \n",
       " 23        NaN        NaN    (34.7%)        NaN        NaN        NaN   \n",
       " \n",
       "    Unnamed: 6  Unnamed: 7              95%  \n",
       " 0         NaN         NaN       Confidence  \n",
       " 1           P        Mean  Interval of the  \n",
       " 2         NaN         NaN              NaN  \n",
       " 3       value  Difference      Differences  \n",
       " 4         NaN         NaN              NaN  \n",
       " 5         NaN         NaN      Lower Upper  \n",
       " 6         NaN         NaN              NaN  \n",
       " 7         NaN         NaN              NaN  \n",
       " 8         NaN         NaN              NaN  \n",
       " 9         NaN         NaN              NaN  \n",
       " 10        NaN         NaN              NaN  \n",
       " 11      0.078       0.484     -0.055 1.023  \n",
       " 12        NaN         NaN              NaN  \n",
       " 13        NaN         NaN              NaN  \n",
       " 14        NaN         NaN              NaN  \n",
       " 15        NaN         NaN              NaN  \n",
       " 16        NaN         NaN              NaN  \n",
       " 17        NaN         NaN              NaN  \n",
       " 18        NaN         NaN              NaN  \n",
       " 19        NaN         NaN              NaN  \n",
       " 20      0.122       2.100     -0.565 4.766  \n",
       " 21        NaN         NaN              NaN  \n",
       " 22        NaN         NaN              NaN  \n",
       " 23        NaN         NaN              NaN  ]"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "extract_pdf_tables(df2['full_pdf'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "3b1ade85",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
